Phreesia (PHR) 10-K 15 Mar 24 2024 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Jan. 31, 2024	Mar. 06, 2024	Jul. 31, 2023
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Jan. 31, 2024
Current Fiscal Year End Date	--01-31
Document Transition Report	false
Entity File Number	001-38977
Entity Registrant Name	PHREESIA, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-2275479
Entity Address, Address Line One	1521 Concord Pike
Entity Address, Address Line Two	Suite 301 PMB 221
Entity Address, City or Town	Wilmington
Entity Address, State or Province	DE
Entity Address, Postal Zip Code	19803
City Area Code	888
Local Phone Number	654-7473
Title of 12(b) Security	Common stock, $0.01 par value per share
Trading Symbol	PHR
Security Exchange Name	NYSE
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 1,617,063,047
Entity Common Stock, Shares Outstanding (in shares)		56,387,472
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant’s Definitive Proxy Statement relating to its 2024 Annual Meeting of Stockholders to be filed hereafter are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated.
Amendment Flag	false
Entity Central Index Key	0001412408
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	FY

Audit Information

Audit Information	12 Months Ended
	Jan. 31, 2024
Audit Information [Abstract]
Auditor Name	KPMG LLP
Auditor Location	Pittsburgh, PA
Auditor Firm ID	185

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jan. 31, 2024	Jan. 31, 2023
Current:
Cash and cash equivalents	$ 87,520,000	$ 176,683,000
Settlement assets	28,072,000	22,599,000
Accounts receivable, net of allowance for doubtful accounts of $1,392 and $1,053 as of January 31, 2024 and 2023, respectively	64,863,000	51,394,000
Deferred contract acquisition costs	768,000	1,056,000
Prepaid expenses and other current assets	14,461,000	10,709,000
Total current assets	195,684,000	262,441,000
Property and equipment, net of accumulated depreciation and amortization of $76,859 and $59,847 as of January 31, 2024 and 2023, respectively	16,902,000	21,670,000
Capitalized internal-use software, net of accumulated amortization of $45,769 and $37,236 as of January 31, 2024 and 2023, respectively	46,139,000	35,150,000
Operating lease right-of-use assets	266,000	569,000
Deferred contract acquisition costs	986,000	1,754,000
Intangible assets, net of accumulated amortization of $4,925 and $2,549 as of January 31, 2024 and 2023, respectively	31,625,000	11,401,000
Deferred tax asset	0	81,000
Goodwill	75,845,000	33,736,000
Other assets	2,879,000	3,255,000
Total Assets	370,326,000	370,057,000
Current:
Settlement obligations	28,072,000	22,599,000
Current portion of finance lease liabilities and other debt	6,056,000	5,172,000
Current portion of operating lease liabilities	393,000	934,000
Accounts payable	8,480,000	10,836,000
Accrued expenses	37,130,000	21,810,000
Deferred revenue	24,113,000	17,688,000
Other current liabilities	5,875,000	0
Total current liabilities	110,119,000	79,039,000
Long-term finance lease liabilities and other debt	5,400,000	2,725,000
Operating lease liabilities, non-current	134,000	349,000
Long-term deferred revenue	97,000	125,000
Long-term deferred tax liabilities	270,000	0
Other long-term liabilities	2,857,000	0
Total Liabilities	118,877,000	82,238,000
Commitments and contingencies (Note 11)
Stockholders’ Equity:
Preferred stock, undesignated, $0.01 par value—20,000,000 shares authorized as of both January 31, 2024 and 2023; no shares issued or outstanding as of January 31, 2024 and 2023, respectively	0	0
Common stock, $0.01 par value—500,000,000 shares authorized as of both January 31, 2024 and 2023; 57,709,762 and 54,187,172 shares issued as of January 31, 2024 and 2023, respectively	577,000	542,000
Additional paid-in capital	1,039,361,000	926,957,000
Accumulated deficit	(742,969,000)	(606,084,000)
Treasury stock, at cost, 1,355,169 and 971,236 shares as of January 31, 2024 and 2023, respectively	(45,520,000)	(33,596,000)
Total Stockholders’ Equity	251,449,000	287,819,000
Total Liabilities and Stockholders’ Equity	$ 370,326,000	$ 370,057,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jan. 31, 2024	Jan. 31, 2023
Statement of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 1,392	$ 1,053
Accumulated depreciation and amortization, property and equipment	76,859	59,847
Accumulated amortization of capitalized internal-use software	45,769	37,236
Accumulated amortization of intangible assets	$ 4,925	$ 2,549
Preferred stock par value (in usd per share)	$ 0.01	$ 0.01
Preferred stock authorized (in shares)	20,000,000	20,000,000
Preferred stock issued (in shares)	0	0
Preferred stock outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	500,000,000	500,000,000
Common stock, shares issued (in shares)	57,709,762	54,187,172
Treasury stock (in shares)	1,355,169	971,236

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2022
Revenue:
Total revenues	$ 356,299	$ 280,910	$ 213,233
Expenses:
Cost of revenue (excluding depreciation and amortization)	61,025	58,944	42,669
Payment processing expense	62,986	50,323	38,719
Sales and marketing	147,008	151,263	106,421
Research and development	112,346	91,244	52,265
General and administrative	79,926	80,384	68,674
Depreciation	17,584	17,988	14,985
Amortization	11,903	7,316	6,317
Total expenses	492,778	457,462	330,050
Operating loss	(136,479)	(176,552)	(116,817)
Other income (expense), net	44	(175)	(78)
Loss on extinguishment of debt	(1,118)	0	0
Interest income (expense), net	2,211	1,064	(1,084)
Total other income (expense), net	1,137	889	(1,162)
Loss before provision for income taxes	(135,342)	(175,663)	(117,979)
Provision for income taxes	(1,543)	(483)	(182)
Net loss	$ (136,885)	$ (176,146)	$ (118,161)
Net loss per share attributable to common stockholders - basic (in dollars per share)	$ (2.51)	$ (3.36)	$ (2.37)
Net loss per share attributable to common stockholders - diluted (in dollars per share)	$ (2.51)	$ (3.36)	$ (2.37)
Weighted-average common shares outstanding - basic (in shares)	54,561,449	52,440,067	49,888,436
Weighted-average common shares outstanding - diluted (in shares)	54,561,449	52,440,067	49,888,436
Subscription and related services
Revenue:
Total revenues	$ 165,436	$ 128,975	$ 95,514
Payment processing fees
Revenue:
Total revenues	94,610	78,368	65,201
Network solutions
Revenue:
Total revenues	$ 96,253	$ 73,567	$ 52,518

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common stock	Additional paid-in capital	Accumulated deficit	Treasury stock
Beginning balance, stockholders' equity (in shares) at Jan. 31, 2021		44,880,883
Beginning balance, stockholders' equity at Jan. 31, 2021	$ 263,306	$ 449	$ 579,599	$ (311,777)	$ (4,965)
Stockholders’ Equity
Net loss	(118,161)			(118,161)
Stock-based compensation expense	$ 29,668		29,668
Exercise of stock options and vesting of restricted stock units (in shares)	1,439,186	1,997,551
Exercise of stock options and vesting of restricted stock units	$ 4,143	$ 20	4,123
Issuance of common stock for employee stock purchase plan (in shares)		42,530
Issuance of common stock for employee stock purchase plan	1,506		1,506
Treasury stock from vesting of restricted stock units - satisfaction of tax withholdings	(8,995)				(8,995)
Issuance of common stock in follow-on public offering, net (in shares)		5,175,000
Issuance of common stock in follow-on public offering, net	245,813	$ 52	245,761
Ending balance, stockholders' equity (in shares) at Jan. 31, 2022		52,095,964
Ending balance, stockholders' equity at Jan. 31, 2022	417,280	$ 521	860,657	(429,938)	(13,960)
Stockholders’ Equity
Net loss	(176,146)			(176,146)
Stock-based compensation expense	$ 52,506		52,506
Exercise of stock options and vesting of restricted stock units (in shares)	311,743	1,626,123
Exercise of stock options and vesting of restricted stock units	$ 1,531	$ 16	1,515
Issuance of common stock for employee stock purchase plan (in shares)		162,154
Issuance of common stock for employee stock purchase plan	3,472	$ 2	3,470
Issuance of stock for share-settled bonus awards (in shares)		302,931
Issuance of stock for share-settled bonus awards	8,812	$ 3	8,809
Treasury stock from vesting of restricted stock units - satisfaction of tax withholdings	$ (19,636)				(19,636)
Ending balance, stockholders' equity (in shares) at Jan. 31, 2023	54,187,172	54,187,172
Ending balance, stockholders' equity at Jan. 31, 2023	$ 287,819	$ 542	926,957	(606,084)	(33,596)
Stockholders’ Equity
Net loss	(136,885)			(136,885)
Stock-based compensation expense	$ 63,981		63,981
Exercise of stock options and vesting of restricted stock units (in shares)	249,247	1,779,430
Exercise of stock options and vesting of restricted stock units	$ 862	$ 18	844
Issuance of common stock for employee stock purchase plan (in shares)		141,121
Issuance of common stock for employee stock purchase plan	3,235	$ 1	3,234
Issuance of stock for share-settled bonus awards (in shares)		354,817
Issuance of stock for share-settled bonus awards	9,041	$ 4	9,037
Treasury stock from vesting of restricted stock units - satisfaction of tax withholdings	(11,924)				(11,924)
Issuance of common stock as consideration in business combinations (in shares)		1,247,222
Issuance of common stock as consideration in business combinations	$ 35,320	$ 12	35,308
Ending balance, stockholders' equity (in shares) at Jan. 31, 2024	57,709,762	57,709,762
Ending balance, stockholders' equity at Jan. 31, 2024	$ 251,449	$ 577	$ 1,039,361	$ (742,969)	$ (45,520)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2022
Operating activities:
Net loss	$ (136,885)	$ (176,146)	$ (118,161)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	29,487	25,304	21,302
Stock-based compensation expense	71,613	58,775	36,144
Amortization of deferred financing costs and debt discount	321	310	288
Loss on extinguishment of debt	1,118	0	0
Cost of Phreesia hardware purchased by customers	1,619	1,598	672
Deferred contract acquisition costs amortization	1,056	1,696	2,211
Non-cash operating lease expense	702	1,768	1,004
Change in fair value of contingent consideration liabilities	0	0	258
Deferred taxes	228	434	143
Changes in operating assets and liabilities:
Accounts receivable	(11,205)	(11,132)	(10,216)
Prepaid expenses and other assets	(2,209)	250	(7,192)
Deferred contract acquisition costs	0	(427)	(3,349)
Accounts payable	(1,993)	4,774	2,881
Accrued expenses and other liabilities	14,195	2,720	(2,983)
Lease liabilities	(1,156)	(1,302)	(1,060)
Deferred revenue	731	1,255	3,348
Net cash used in operating activities	(32,378)	(90,123)	(74,710)
Investing activities:
Acquisitions, net of cash acquired	(14,573)	0	(34,423)
Capitalized internal-use software	(19,291)	(21,471)	(12,385)
Purchases of property and equipment	(5,806)	(4,732)	(18,420)
Net cash used in investing activities	(39,670)	(26,203)	(65,228)
Financing activities:
Proceeds from issuance of common stock in equity offerings, net of underwriters' discounts and commissions	0	0	245,813
Proceeds from issuance of common stock upon exercise of stock options	955	1,603	4,889
Treasury stock to satisfy tax withholdings on stock compensation awards	(12,176)	(19,383)	(8,995)
Proceeds from employee stock purchase plan	3,209	3,321	1,979
Finance lease payments	(6,779)	(5,731)	(4,267)
Constructive financing	1,688	0	0
Principal payments on financing agreements	(600)	(216)	(1,039)
Debt issuance costs and loan facility fee payments	(1,321)	(397)	(125)
Financing payments of acquisition-related liabilities	(1,333)	0	(3,286)
Debt extinguishment costs	(758)	0	0
Net cash (used in) provided by financing activities	(17,115)	(20,803)	234,969
Net (decrease) increase in cash and cash equivalents	(89,163)	(137,129)	95,031
Cash and cash equivalents—beginning of year	176,683	313,812	218,781
Cash and cash equivalents—end of year	87,520	176,683	313,812
Supplemental information of non-cash investing and financing activities:
Right of use assets acquired in exchange for operating lease liabilities	398	0	81
Property and equipment acquisitions through finance leases	7,438	526	7,394
Purchase of property and equipment and capitalized software included in accounts payable and accrued liabilities	1,299	2,345	1,124
Receivables for cash in-transit on stock option exercises	0	97	169
Capitalized stock based compensation	1,415	1,372	489
Issuance of stock to settle liabilities for stock-based compensation	12,276	12,284	0
Deferred consideration liabilities payable in business combinations	8,732	0	0
Acquisitions, net of cash acquired	35,321	0	0
Capitalized software acquired through vendor financing	2,047	0	0
Cash paid for:
Interest	1,306	763	802
Income taxes	$ 37	$ 39	$ 49

Background and liquidity

Background and liquidity	12 Months Ended
	Jan. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Background and liquidity	Background and liquidity (a) Background Phreesia, Inc. (the "Company") is a leading provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations and improve health outcomes by helping patients take a more active role in their care. The Company's solutions include SaaS-based integrated tools that manage patient access, registration and payments. Additionally, the Company has tools to communicate with patients about their health that have demonstrated increased rates of preventive care and vaccinations. Additionally, Phreesia's solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to better understand their patients and connect them to needed services, resulting in improved health outcomes. The Company also provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. Phreesia's solutions also include additional products and services such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise. Phreesia offers its healthcare services clients the ability to lease tablets ("PhreesiaPads") and on-site kiosks ("Arrivals Kiosks") along with their monthly subscription. The Company was formed in May 2005. b) Liquidity Since the Company commenced operations, it has not generated sufficient revenue to meet its operating expenses and has continued to incur significant net losses. To date, the Company has primarily relied upon the proceeds from issuances of common stock, debt and preferred stock to fund its operations as well as sales of Company products and services in the normal course of business. Management believes that net losses and negative cash flows will continue for at least the next year. On December 4, 2023, the Company entered into a credit agreement with Capital One N.A. containing a senior secured asset-based revolving credit facility with an available borrowing capacity of up to $50.0 million (the “Capital One Credit Facility”). On December 4, 2023, the Company also terminated the Third SVB Facility. See Note 6 - Finance Leases and other debt for additional information regarding the Capital One Credit Facility and the termination of the Third SVB Facility. Management believes that the Company’s cash and cash equivalents at January 31, 2024, along with cash generated in the normal course of business and available borrowing capacity under the Capital One Credit Facility, are sufficient to fund its operations for at least the next 12 months.

Basis of presentation

Basis of presentation	12 Months Ended
	Jan. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of presentation	Basis of presentation (a) Consolidated financial statements The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("GAAP") and regulations of the Securities and Exchange Commission ("SEC") regarding annual financial reporting and include the accounts of Phreesia, Inc; its branch operation in Canada and its consolidated subsidiaries (or collectively, the "Company"). (b) Fiscal year The Company’s fiscal year ends on January 31. References to fiscal 2024, 2023 and 2022 refer to the fiscal years ending on January 31, 2024, 2023 and 2022, respectively.

Summary of significant accounti

Summary of significant accounting policies	12 Months Ended
	Jan. 31, 2024
Accounting Policies [Abstract]
Summary of significant accounting policies	Summary of significant accounting policies (a) Use of estimates The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The most significant assumptions and estimates relate to the allowance for doubtful accounts, capitalized internal-use software, the determination of the useful lives of property and equipment, the fair value of securities underlying stock-based compensation, the fair value of identifiable assets and liabilities and deferred consideration in business acquisitions. (b) Revenue recognition The Company evaluates its contractual arrangements to determine the performance obligations and transaction prices. Revenue is allocated to each performance obligation and recognized when the related performance obligations are satisfied. See Note 5 for additional information regarding ASC 606, Revenue from Contracts with Customers , as well as for additional details about the Company's products and service lines. (c) Concentrations of credit risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, accounts receivable and settlement assets. The Company’s cash and cash equivalents are held by established financial institutions. The Company does not require collateral from its customers and generally requires payment within 30 to 60 days of billing. Settlement assets are amounts due from well-established payment processing companies and normally take one two The Company’s customers are primarily healthcare services organizations located in the United States as well as pharmaceutical companies. The Company did not have any individual customers that represented more than 10% of total revenues for the years ended January 31, 2024, 2023 and 2022. As of both January 31, 2024 and January 31, 2023, the Company had receivables from at least one entity that accounted for at least 10% of total accounts receivable. (d) Risks and uncertainties The Company is subject to a variety of risk factors, including the economy, data privacy and security laws and government regulations. Additionally, the Company is subject to other risks associated with the markets in which it operates including reliance on third-party vendors, partners, and service providers. The Company supplements its workforce with contractors and consultants, including a substantial number of contractors and consultants in international locations. Certain of the Company's service providers, including certain third-party software developers, are located in international locations subject to warfare and/or political and economic instability, such as Ukraine and India. As with any business, operation of the Company involves risk, including the risk of service interruption impacting the operations of the Company's business and the Company's customer’s facilities below expected levels of operation, shut downs due to the breakdown or failure of information technology and communications systems, changes in laws or regulations, political and economic instability, or catastrophic events such as fires, earthquakes, floods, explosions, global health concerns such as pandemics or other similar occurrences affecting the delivery of our productions and services. The occurrence of any of these events could significantly reduce or eliminate revenues generated, or significantly increase the expenses of the Company's operations, adversely impacting the Company’s operating results and the Company's ability to meet the Company's obligations and commitments. See Note 6 - Finance leases and other debt and Note 11 - Commitments and contingencies, for a summary of our contractual commitments as of January 31, 2024. (e) Cost of revenue (excluding depreciation and amortization) Cost of revenue (excluding depreciation and amortization) primarily consists of personnel expenses for implementation and technical support, infrastructure costs for operation of our solutions such as hosting fees, and certain fees paid to various third-party providers for the use of their technology, as well as costs to verify insurance eligibility and benefits. Personnel expenses consist of salaries, stock-based compensation and benefits. (f) Payment processing expense Payment processing expense consists primarily of interchange fees set by payment card networks that are ultimately paid to the card-issuing financial institution, and assessment fees paid to payment card networks, and fees paid to third-party payment processors and gateways. (g) Sales and marketing Sales and marketing expense consists primarily of personnel costs, including salaries, stock-based compensation, benefits, bonuses and commission costs for our sales and marketing personnel. Sales and marketing expense also includes costs for advertising, promotional and other marketing activities, as well as certain fees paid to various third-party partners for sales lead generation. Advertising is expensed as incurred. Advertising expense was $1,900, $2,634 and $4,007 for the fiscal years ended January 31, 2024, 2023 and 2022, respectively. (h) Research and development Research and development expense consists of costs for the design, development, testing and enhancement of the Company’s products and services that do not meet the criteria for capitalization as internal-use software. These costs consist primarily of personnel costs, including salaries, stock-based compensation and benefits for our development personnel. Research and development expense also includes third-party partner fees and third-party consulting fees. (i) General and administrative General and administrative expense consists primarily of personnel costs, including salaries, stock-based compensation and benefits for our executive, finance, legal, human resources, information technology, and other administrative personnel. General and administrative expense also includes consulting, legal, security, accounting services and allocated overhead. (j) Depreciation Depreciation represents depreciation expense for PhreesiaPads and Arrivals Kiosks (collectively, Phreesia hardware), data center and other computer hardware, purchased computer software, furniture and fixtures and leasehold improvements. (k) Amortization Amortization primarily represents amortization of our capitalized internal-use software related to the Company's solutions as well as amortization of acquired intangible assets. (l) Cash and cash equivalents The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents. The Company's money market accounts meet the definition of cash equivalents. (m) Settlement assets Settlement assets represent amounts due from the Company’s payment processor for customer electronic processing transactions. Settlement assets are typically settled within one two (n) Settlement obligations Settlement obligations represent amounts due to customers for electronic processing transactions that have not been funded by the Company due to timing of settlement from the Company’s payment processor. (o) Accounts receivable Accounts receivable represent trade receivables, net of allowances for doubtful accounts. The Company estimates the allowance for doubtful accounts as its current estimate of expected credit loss over the life of the instrument. The Company determines the allowance based on historical trends of accounts receivable balances that have been written off and specific account analysis of at-risk customers, the length of time accounts are past due, a customer's current ability to pay its obligations to the Company, the condition of the industry as a whole, as well as expected future changes in credit losses. Accounts receivable are written off at the point that internal collections efforts have been exhausted. As of January 31, 2024 and 2023, the Company has reserved $1,392 and $1,053, respectively, for the allowance for doubtful accounts. Accounts receivable also includes unbilled accounts receivable (see Contract balances in Note 5(f)). (p) Property and equipment Property and equipment, including PhreesiaPads and Arrivals Kiosks, are stated at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the related assets. The estimated useful lives of the Company’s property and equipment have been estimated to be between three Upon sale or disposition of property and equipment, the cost and related accumulated depreciation are removed from their respective accounts and any gain or loss is reflected in the consolidated statements of operations. (q) Capitalized internal-use software The Company capitalizes certain costs incurred for the development of computer software for internal use pursuant to ASC 350-40, Intangibles—Goodwill and Other—Internal use software . These costs relate to the development of its solutions. The Company capitalizes the costs during the development of the project, when it is determined that it is probable that the project will be completed, and the software will be used as intended. Costs related to preliminary project activities, post-implementation activities, training and maintenance are expensed as incurred. Internal-use software is amortized on a straight-line basis over its estimated useful life, which is generally three (r) Business combinations The Company uses its best estimates and assumptions to accurately assign fair value to the tangible and intangible assets acquired and liabilities assumed at the acquisition date. The Company’s estimates are inherently uncertain and subject to refinement. During the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the fair value of these tangible and intangible assets acquired and liabilities assumed, with the corresponding offset to goodwill. The Company continues to collect information and reevaluate these estimates and assumptions quarterly and records any adjustments to its estimates to goodwill provided that the Company is within the measurement period. Upon the conclusion of the measurement period or final determination of the fair value of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the consolidated statement of operations. When applicable, the consideration transferred for business combinations includes the acquisition-date fair value of deferred consideration liabilities. The Company recognizes interest expense to accrete deferred consideration liabilities to their settlement amount. (s) Goodwill and intangible assets Goodwill represents the excess of the consideration transferred over the fair value of the underlying net tangible and intangible assets acquired and liabilities assumed in connection with business combinations accounted for using the acquisition method of accounting. Goodwill is not amortized, but instead goodwill is required to be tested for impairment annually and under certain circumstances. We perform such testing of goodwill in the fourth quarter of each fiscal year, or as events occur or circumstances change that would more likely than not reduce the fair value below its carrying amount. The testing of goodwill is performed at the reporting unit level. The Company’s reporting unit is the same as its operating segment. The test begins with a qualitative assessment to determine whether it is “more likely than not” that the fair value of the reporting unit is less than its carrying amount. If it is concluded that it is “more likely than not” that the fair value of a reporting unit is less than its carrying amount, the Company performs a quantitative goodwill impairment test by calculating the fair value of the reporting unit and comparing that fair value to the carrying value of the reporting unit. If the estimated fair value of the reporting unit is less than its carrying amount, the Company records a goodwill impairment to reduce the carrying amount of goodwill by the amount by which the fair value of the reporting unit is less than its carrying amount. All other intangible assets associated with purchased intangibles, consisting of customer relationships, acquired technology, acquired trademarks and acquired licenses, are recorded at acquisition-date fair value less accumulated amortization and are amortized on a straight-line basis over their estimated remaining economic lives. (t) Long-lived assets Long-lived assets, such as property and equipment, intangible assets, capitalized internal-use software and operating lease right-of-use assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares the undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. There were no impairment charges recognized in the consolidated statements of operations during any of the periods presented. (u) Income taxes An asset and liability approach is used for financial accounting and reporting of current and deferred income taxes. Deferred income tax assets and liabilities are computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future. Such deferred income tax asset and liability computations are based on enacted tax laws and rates applicable to periods in which the differences are expected to affect taxable income or loss. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company follows the guidance in ASC 740, Accounting for Uncertainty in Income Taxes . ASC 740 clarifies the accounting for uncertainty in income taxes recognized in a Company’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC 740 also provides guidance on de-recognition, classification, interest and penalties, accounting in the interim periods, and disclosure. The Company reviews and evaluates tax positions in its major jurisdictions and determines whether or not there are uncertain tax positions that require financial statement recognition and the recording of a tax liability or the reduction of a tax asset. The Company would recognize tax related interest and penalties, if applicable, as a component of its provision for income taxes. (v) Segment information Operating segments are defined as components of an enterprise about which separate financial information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company defines the term “chief operating decision maker” to be its Chief Executive Officer. The Company’s Chief Executive Officer reviews the financial information presented on an entire company basis for purposes of allocating resources and evaluating our financial performance. Accordingly, we have determined that we operate in a single reportable operating segment. Additionally, substantially all of the Company's revenues and long-lived assets are located in the U.S. Since the Company operates in one operating segment and substantially all of the Company's revenues and long-lived assets are located in the U.S., all required financial segment information can be found in the accompanying consolidated financial statements. (w) Stock-based compensation The Company has stock-based compensation plans under which various types of equity-based awards are granted, including stock options, restricted stock units ("RSUs"), performance-based RSUs, and market-based performance stock units ("PSUs"). The compensation for the stock-based awards is recognized in accordance with ASC 718 , Compensation — Stock Compensation , which requires that compensation cost be recognized for awards based on the grant-date fair value of the award. That cost is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the award. For performance-based RSUs, the number of shares expected to vest is estimated at each reporting date based on management's expectations regarding the relevant performance criteria. The Company adjusts stock compensation expense for forfeitures of stock-based compensation awards in the periods the forfeitures occur. The fair value of stock options is estimated at the time of grant using the Black-Scholes option pricing model, which requires the use of inputs and assumptions such as the exercise price of the option, expected term, risk-free interest rate, expected volatility and dividend yield, and the value of the Company's common stock (which is estimated for awards granted prior to our IPO). The Company does not estimate forfeitures in recognizing stock-based compensation expense. The fair value of the RSUs is equal to the fair value of the Company's common stock on the grant date of the award. The fair value of market-based PSUs is estimated at the time of grant using a Monte Carlo simulation which compares Phreesia's projected total shareholder return ("TSR") to the projected TSR of the Russell 3000 Index (the "Peer Group") and estimates the value of shares to be issued based on the vesting conditions of the PSUs. The Monte Carlo simulation requires the use of inputs and assumptions such as the grant-date closing stock price, simulation, expected volatility, correlation coefficient to the Russell 3000 Index, risk-free interest rate and dividend yield. During fiscal 2022, the Company adopted the Phreesia, Inc. 2019 Employee Stock Purchase Plan ("ESPP" or "the Plan"). The Company will record compensation expense based on the grant date fair value per award granted multiplied by the number of awards granted to the employee for the purchase period. The number of awards granted to the employee for the purchase period is equal to the expected employee contributions divided by 85% of the closing stock price on the offering date. For liability-classified performance based stock bonus awards, at the beginning of the year, the Company offers eligible employees the option to elect to receive their year-end performance bonus in stock. Bonuses settled in stock are accounted for as stock-based compensation awards vesting based on a performance condition and are classified as liabilities because they represent a liability settled in a variable number of shares. During fiscal 2023, the Company adopted the 2023 Inducement Award Plan (the "Inducement Plan"). The Inducement Plan allows the Company to grant equity-based incentive awards including stock options, RSUs and PSUs to employees of acquired companies to induce them to join the Company. See Note 8 - Equity-based compensation, for additional information on stock-based compensation. (x) Fair value of financial instruments Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for the sale of an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are required to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market. Level 3—Unobservable inputs which are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. (y) Equity offering costs The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs will be recorded in stockholders’ equity as a reduction of additional paid-in capital generated as a result of the offering, to the extent there are sufficient proceeds. Should the equity financing no longer be considered probable of being consummated, all deferred offering costs would be charged to operating expenses in the accompanying consolidated statement of operations. (z) Foreign currency The Company has a branch office in Canada that provides operational support. The functional currency of the Company’s foreign branch is the U.S. dollar. Accordingly, assets and liabilities of the Company’s foreign branch are re-measured into U.S. dollars at the exchange rates in effect at the reporting date with differences recorded as transaction gains and losses within other income (expense), net. (aa) New accounting pronouncements Impact of recently adopted accounting pronouncements During the year ended January 31, 2024, the Company did not adopt any accounting pronouncements that materially impacted the Company's financial statements. Recent accounting pronouncements not yet adopted In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) 2023-07, Segment Reporting. The new standard requires enhanced disclosures about significant segment expenses and other segment items and requires companies to disclose all annual disclosures about segments in interim periods. The new standard also permits companies to disclose more than one measure of segment profit or loss, requires disclosure of the title and position of the Chief Operating Decision Maker, and requires companies with a single reportable segment to provide all disclosures required by Topic 280 – Segment Reporting. The new standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. Companies are required to apply ASU 2023-07 retrospectively to all periods presented. The Company is currently evaluating the impact that ASU 2023-07 will have on its financial statements and related disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The provisions of ASU 2023-09 are effective for annual periods beginning after December 15, 2024; early adoption is permitted. The Company is currently evaluating the impact that ASU 2023-09 will have on its financial statements and related disclosures.

Composition of certain financia

Composition of certain financial statement captions	12 Months Ended
	Jan. 31, 2024
Composition Of Certain Financial Statement [Abstract]
Composition of certain financial statement captions	Composition of certain financial statement captions (a) Accrued expenses Accrued expenses at January 31, 2024 and 2023 are as follows: January 31, 2024 2023 Payroll-related expenses and taxes $ 8,981 $ 4,461 Stock-based compensation liability 5,890 5,884 Payment processing fees liability 6,008 4,796 Acquisition-related liabilities 1,888 96 Income and other tax liabilities 3,042 1,491 Information technology services 5,927 2,249 Other 5,394 2,833 Total $ 37,130 $ 21,810 (b) Other current liabilities and other long-term liabilities Other current liabilities and other long-term liabilities as of January 31, 2024 were $5,875 and $2,857, respectively. There were no other current liabilities and other long-term liabilities recorded as of January 31, 2023. Other current liabilities and other long-term liabilities represent deferred consideration liabilities payable to the former equity holders of ConnectOnCall. See Note 16 - Acquisitions for additional information regarding the acquisition of ConnectOnCall. (c) Property and equipment Property and equipment at January 31, 2024 and 2023 are as follows: Useful life January 31, 2024 2023 PhreesiaPads and Arrivals Kiosks 3 $ 18,610 $ 17,932 Computer equipment 3 62,888 54,485 Computer software 3 to 5 11,687 8,571 Hardware development 3 576 529 Total property and equipment $ 93,761 $ 81,517 Less: accumulated depreciation (76,859) (59,847) Property and equipment — net $ 16,902 $ 21,670 Depreciation expense related to property and equipment amounted to $17,584, $17,988 and $14,985 for the fiscal years ended January 31, 2024, 2023 and 2022, respectively. Assets acquired under finance leases included in computer equipment were $35,250 and $27,813 at January 31, 2024 and 2023, respectively. Accumulated amortization of assets under finance leases was $27,399 and $20,657 at January 31, 2024 and 2023, respectively. See Note 10 - Leases for additional information regarding finance leases. (d) Capitalized internal-use software For the fiscal years ended January 31, 2024, 2023 and 2022, the Company capitalized $19,521, $23,604 and $12,830 of costs related to the Company's solutions, respectively. During the fiscal years ended January 31, 2024, 2023 and 2022 amortization expense related to capitalized internal-use software was $9,527, $5,945 and $5,664, respectively. (e) Intangible assets and goodwill On June 30, 2023, the Company entered into an agreement to acquire Comsort, Inc. d/b/a MediFind ("MediFind") (the "MediFind Acquisition"). The Company acquired certain intangible assets and goodwill in connection with the MediFind Acquisition. See Note 16 - Acquisitions for additional information regarding the MediFind Acquisition. On August 11, 2023, the Company entered into an agreement to acquire Access eForms, LLC ("Access") (the "Access Acquisition"). The Company acquired certain intangible assets and goodwill in connection with the Access Acquisition. See Note 16 - Acquisitions for additional information regarding the Access Acquisition. On October 3, 2023, the Company entered into an agreement to acquire ConnectOnCall.com, LLC ("ConnectOnCall") (the "ConnectOnCall Acquisition"). The Company acquired certain intangible assets and goodwill in connection with the ConnectOnCall Acquisition. See Note 16 - Acquisitions for additional information regarding the ConnectOnCall Acquisition. The tables set forth below include intangible assets and goodwill acquired in all of the Company's acquisitions. The following presents the details of intangible assets as of January 31, 2024 and 2023. Useful Life January 31, (years) 2024 2023 Acquired technology 5 to 7 $ 9,310 $ 1,410 Customer relationship 7 to 15 17,940 6,340 License 15 6,200 6,200 Trademarks 15 3,100 — Total intangible assets, gross carrying value $ 36,550 $ 13,950 Less: accumulated amortization (4,925) (2,549) Net carrying value $ 31,625 $ 11,401 The weighted average remaining useful life for acquired technology in years was 6.0 and 2.7 as of January 31, 2024 and 2023, respectively. The remaining useful life for customer relationships in years was 12.4 and 8.3 as of January 31, 2024 and 2023, respectively. The remaining useful life for the license to the Patient Activation Measure ("PAM"®) in years was 12.8 and 13.8 as of January 31, 2024 and 2023, respectively. The remaining useful life for the trademarks in years was 14.5 as of January 31, 2024. Amortization expense associated with intangible assets for the fiscal years ended January 31, 2024, 2023 and 2022 was $2,376, $1,371 and $653, respectively. The estimated amortization expense for intangible assets for the next five years and thereafter is as follows as of January 31, 2024: January 31, 2024 2025 $ 3,481 2026 3,450 2027 3,157 2028 3,157 Thereafter 18,380 Total $ 31,625 The following table presents a roll-forward of goodwill for the years ended January 31, 2023 and 2024: Balance at January 31, 2022 $ 33,621 Measurement period adjustments to goodwill during the year ended January 31, 2023 115 Balance at January 31, 2023 $ 33,736 Goodwill acquired during the year ended January 31, 2024 42,109 Balance at January 31, 2024 $ 75,845 During the quarter ended October 31, 2023, the Company completed its quarterly triggering event assessments and determined that the decline in the market value of its publicly-traded stock, which resulted in a corresponding decline in its market capitalization, constituted a triggering event. Due to the decline in the Company’s market capitalization during the quarter ended October 31, 2023 the Company evaluated whether changes in the Company’s market capitalization indicated that the carrying value of goodwill in the Company’s single reporting unit was impaired. As of October 31, 2023, the Company’s market capitalization exceeded the carrying value of the Company’s equity by over 100%. As a result, the Company did not believe that changes in the Company’s market capitalization during the quarter ended October 31, 2023 indicated that that the carrying amount of the Company’s goodwill was impaired as of October 31, 2023. As of January 31, 2024, the Company's market capitalization also exceeded the carrying amount of the Company's equity by over 100%. As a result, the Company does not believe that the Company’s goodwill is impaired as of January 31, 2024. No other triggering events occurred during fiscal 2024. The Company did not record any impairments of goodwill during the years ended January 31, 2024, 2023 or 2022. Additions to goodwill during the year ended January 31, 2023 represent measurement period adjustments for the acquisition of Insignia Health, LLC (the "Insignia Acquisition"). Substantially all of the Company's goodwill is amortizable for tax purposes. (f) Accounts receivable Accounts Receivable as of January 31, 2024 and 2023 are as follows: January 31, 2024 2023 Billed $ 62,880 $ 51,458 Unbilled 3,375 989 Total accounts receivable, gross $ 66,255 $ 52,447 Less: accounts receivable allowances (1,392) (1,053) Total accounts receivable $ 64,863 $ 51,394 Activity in the Company's allowance for doubtful accounts was as follows for the years ended January 31, 2024 and 2023: Balance, January 31, 2022 $ 863 Bad debt expense 587 Write-offs and adjustments (397) Balance, January 31, 2023 $ 1,053 Bad debt expense 377 Increases due to acquisitions 681 Write-offs and adjustments (719) Balance, January 31, 2024 $ 1,392 The Company’s allowance for doubtful accounts represents the current estimate of expected future losses based on prior bad debt experience as well as considerations for specific customers as applicable. The Company's accounts receivable are considered past due when they are outstanding past the due date listed on the invoice to the customer. The Company writes off accounts receivable and removes the associated allowance for doubtful accounts when the Company deems the receivables to be uncollectible. (g) Prepaid and other current assets Prepaid and other current assets as of January 31, 2024 and 2023 are as follows: January 31, 2024 2023 Prepaid software and business systems $ 4,922 $ 3,426 Prepaid data center expenses 3,872 2,389 Prepaid insurance 1,257 1,552 Other prepaid expenses and other current assets 4,410 3,342 Total prepaid and other current assets $ 14,461 $ 10,709 (h) Cloud computing implementation costs

Revenue and contract costs

Revenue and contract costs	12 Months Ended
	Jan. 31, 2024
Revenue from Contract with Customer [Abstract]
Revenue and contract costs	Revenue and contract costs The Company generates revenue primarily from providing integrated SaaS-based software and payment solutions for the healthcare industry. The Company derives revenue from subscription fees and related services generated from the Company’s healthcare services clients for access to the Company's solutions, payment processing fees based on patient payment volume, and fees from life sciences and payer clients for delivering qualified direct communications to patients who voluntarily opt in to receive this type of engagement using the Company's solutions. The Company accounts for revenue from contracts with customers by applying the requirements of ASC 606. Accordingly, the Company determines revenue recognition through the following steps: • identification of the contract, or contracts, with a customer; • identification of the performance obligations in the contract; • determination of the transaction price; • allocation of the transaction price to the performance obligations in the contract; and • recognition of revenue when, or as, the Company satisfies a performance obligation. Revenues are recognized when control of these services is transferred to the Company’s customers, in an amount that reflects the consideration it expects to be entitled to in exchange for those services. The majority of the Company’s contracts with customers contain multiple performance obligations. For these contracts, the Company accounts for individual performance obligations separately when they are distinct. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Company determines the standalone selling prices based on our overall pricing objectives, taking into consideration market conditions, historical pricing information as priced in previous bundled contracts, as well as other factors such as product, customer type and geographic area. We typically establish a range of SSPs for each of our performance obligations. We use the residual method to the estimate the SSP for certain performance obligations with highly variable pricing. (a) Subscription and related services In most cases, the Company generates subscription fees from clients based on the number of healthcare services clients that utilize the Company's solutions and subscription fees for the Company’s self-service intake tablets (PhreesiaPads), on-site kiosks (Arrivals Kiosks) and any other solutions. The Company’s healthcare services clients are typically billed monthly in arrears, though in some instances healthcare services clients may opt to be billed monthly, quarterly or annually in advance. Subscription fees are typically auto-debited from client’s accounts every month. Revenue for healthcare services client subscriptions is recognized over the term of the respective healthcare services client contract. Substantially all of the Company’s subscription arrangements are considered service contracts, and the customer does not have the right to take possession of the software. Revenue for related services is recognized as it is delivered if the services are distinct from the subscription service and is recognized over the remaining non-cancelable subscription term if it is not distinct from the subscription service. In certain arrangements, the Company leases its PhreesiaPads and Arrivals Kiosks through operating leases to its customers. Accordingly, these revenue transactions are accounted for using ASC 842, Leases . The amount of subscription and related services revenues recorded pursuant to ASC 842 for the leasing of the Company’s PhreesiaPads and Arrivals Kiosks was $10,307, $10,197 and $6,489 for the years ended January 31, 2024, 2023 and 2022, respectively. In addition, subscription and related services includes certain fees from clients for professional services associated with implementation services as well as travel and expense reimbursements, shipping and handling fees, sales of Phreesia hardware (PhreesiaPads and Arrivals Kiosks), on-site support and training. Certain professional services for implementation are not distinct from the Company's solutions and are therefore recognized over the term of the contract. Revenue from sales of distinct professional services, Phreesia hardware and training are recognized in the period they are delivered to clients. (b) Payment processing fees The Company generates revenue from payment processing fees based on the levels of patient payment volume resulting from credit and debit card transactions (dollar value and number of card transactions) processed through Phreesia’s payment facilitator model. Payment processing fees are generally calculated as a percentage of the total transaction dollar value processed and/or a fee per transaction. The remainder of patient payment volume is composed of credit and debit card transactions for which Phreesia acts as a gateway to payment processors, and cash and check transactions. The Company recognizes the payment processing fees when the transaction occurs (i.e., when the processing services are completed). The transaction amount is collected from the cardholder’s bank via the Company’s third-party payment processing partner and the card networks. The transaction amount is then remitted to its customers approximately two The Company acts as the merchant of record for its customers and works with payment card networks and banks so that its customers do not need to manage the complex systems, rules, and requirements of the payment industry. The Company satisfies its performance obligations and therefore recognizes the transaction fees as revenue upon completion of a transaction. Revenue is recognized net of refunds, which arise from reversals of transactions initiated by the Company’s customers. The payment processing fees collected from customers are recognized as revenue on a gross basis as the Company is the principal in the delivery of the managed payment solutions to the customer. The Company has concluded it is the principal because as the merchant of record, it controls the services before delivery to the customer, it is primarily responsible for the delivery of the services to its customers, it has latitude in establishing pricing with respect to the customer and other terms of service, it has sole discretion in selecting the third-party to perform the settlement, and it assumes the credit risk for the transaction processed. The Company also has the unilateral ability to accept or reject a transaction based on criteria established by the Company. As the merchant of record, the Company is liable for settlement of the transactions processed and, accordingly, such costs are included in payment processing fees expense on the accompanying statements of operations. (c) Network solutions The Company's Network solutions revenue includes fees from life sciences companies and payers for qualified direct communications to activate, engage and educate patients who voluntarily opt in to receive this type of engagement about topics critical to their health using the solutions. The Company generates revenue from sales of digital marketing solutions to life sciences companies which is based largely on the delivery of messages at a contracted price per message to patients. Messaging campaigns are sold for a specified number of messages delivered to qualified patients over an expected time frame. Revenue is recognized as the messages are delivered. The Company generates revenue from sales of qualified leads to health plans and other payer organizations which is based largely on the delivery of qualified leads to health plans and other payer organizations at a contracted price per lead. The Company identifies the qualified leads based on direct communications delivered to patients. Revenue for leads is recognized based on our estimate of leads accepted by health plans and other payer organizations. (d) Disaggregation of revenue Revenue from the Company’s contracts with its customers are disaggregated by service offering on the accompanying consolidated statements of operations. The Company’s core service offerings are subscription and related services, payment processing fees, digital marketing solutions sold to life sciences companies and qualified leads sold to health plans and other payer organizations. In addition, substantially all of the Company’s revenue is derived from customers in the United States. (e) Remaining performance obligations The Company does not disclose the value of unsatisfied performance obligations as the majority of its contracts relate to either contracts with an original term of one year or less or contracts with variable consideration (i.e., the Company’s payment processing fees revenue). (f) Contract balances Unbilled accounts receivable is a contract asset related to the delivery of the Company’s subscription and related services and for its life sciences revenue for which the related billings will occur in a future period. Contract assets and contract liabilities are reported on a net basis for each customer contract. Deferred revenue is a contract liability primarily related to billings in advance of revenue recognition from the Company's subscription and life sciences services and, to a lesser extent, professional services and other revenues described above. Deferred revenue is recognized as the Company satisfies its performance obligations. The Company generally invoices its customers in monthly or quarterly installments for subscription services. Accordingly, the deferred revenue balance does not generally represent the total contract value of a subscription arrangement. Deferred revenue that will be recognized during the succeeding 12-month period is recorded as current deferred revenue on the accompanying consolidated balance sheets. Deferred revenue that will be recognized subsequent to the succeeding 12-month period is recorded as long-term deferred revenue on the accompanying consolidated balance sheets. The following table represents a roll-forward of contract assets: January 31, 2024 2023 Beginning Balance $ 989 $ 392 Amount transferred to receivables from beginning balance of contract assets (989) (392) Contract asset additions, net of reclassification to receivables 3,375 989 Ending Balance $ 3,375 $ 989 The following table represents a roll-forward of deferred revenue: January 31, 2024 2023 Beginning Balance $ 17,813 $ 16,558 Revenue recognized that was included in deferred revenue at the beginning of the period (17,388) (16,005) Deferred revenue added from acquisitions 5,665 — Other current year activity in deferred revenue 18,120 17,260 Ending Balance $ 24,210 $ 17,813 (g) Cost to obtain a contract The Company capitalizes certain incremental costs to obtain customer contracts and amortizes these costs over a period of benefit that the Company has estimated to be three these deferred contract acquisition costs to determine whether events or changes in circumstances have occurred that could impact the period of benefit. There were no impairment losses recorded during the periods presented. The following table represents a roll-forward of deferred contract acquisition costs: January 31, 2024 2023 Beginning balance $ 2,810 $ 4,079 Additions to deferred contract acquisition costs — 427 Amortization of deferred contract acquisition costs (1,056) (1,696) Ending balance $ 1,754 $ 2,810 Deferred contract acquisition costs, current (to be amortized in next 12 months) $ 768 $ 1,056 Deferred contract acquisition costs, non-current 986 1,754 Total deferred contract acquisition costs $ 1,754 $ 2,810

Finance leases and other debt

Finance leases and other debt	12 Months Ended
	Jan. 31, 2024
Debt Disclosure [Abstract]
Finance leases and other debt	Finance leases and other debt As of January 31, 2024 and 2023, the Company had the following outstanding finance lease liabilities and other debt: January 31, 2024 2023 Finance leases $ 8,309 $ 7,651 Financing arrangements 3,124 46 Accrued interest and payments 23 200 Total finance lease liabilities and other debt $ 11,456 $ 7,897 Less: current portion of finance lease liabilities and other debt (6,056) (5,172) Long-term finance lease liabilities and other debt $ 5,400 $ 2,725 (a) Finance leases See Note 10 - Leases for more information regarding finance leases. (b) Financing agreements On June 8, 2023, the Company entered into a software licensing financing agreement (the "financing agreement") in order to finance its software, equipment and service licenses. As of January 31, 2024, there was $3,124 in outstanding principal and interest due under the financing agreement. The financing agreement requires the Company to pay $123 per month for 36 months beginning August 2023. The effective interest rate on the financing agreement is 10.5% per annum. (c) Amended and Restated Loan and Security Agreement with SVB On February 28, 2019 (the "Effective Date"), the Company entered into the Amended and Restated Loan and Security Agreement (the "First SVB Facility") that provided for a $20,000 term loan. On May 5, 2020 (the "Second SVB Effective Date"), the Company entered into the Second SVB Facility to modify the First SVB Facility. The Second SVB Facility provided for a revolving credit facility with an initial borrowing capacity of $50,000. On March 28, 2022 (the "Third SVB Effective Date"), the Company entered into a First Loan Modification Agreement to the Second SVB Facility (as amended, the "Third SVB Facility") to increase the borrowing capacity from $50,000 to $100,000 and to reduce the interest rate on the facility. Borrowings under the Third SVB Facility were payable on May 5, 2025. Borrowings under the Third SVB Facility bore interest, which was payable monthly, at a floating rate equal to the greater of 3.25% or the Wall Street Journal Prime Rate minus 0.5%. In addition to principal and interest due under the revolving credit facility, the Company was required to pay an annual commitment fee of approximately $250 per year and a quarterly fee of 0.15% per annum of the average unused revolving line under the facility. On December 4, 2023, the Company terminated the Third SVB Facility. During the fourth quarter of fiscal 2024, the Company recorded a $1,118 loss on extinguishment of debt, which consisted of $612 in fees to terminate the Third SVB Facility and $506 to write-off unamortized deferred financing costs in connection with the termination of the Third SVB Facility. During the fiscal year ended January 31, 2024 and 2023, there was no debt outstanding related to the Third SVB Facility and the Second SVB Facility, respectively. As a result, the Company presented all amortized deferred costs within other assets and amortized unamortized costs over the term of the Third SVB Facility. (d) Capital One Credit Agreement On December 4, 2023, the Company entered into a Credit Agreement (the "Credit Agreement") for a new 5-year $50,000 senior secured asset-based revolving credit facility ("Capital One Credit Facility") maturing in December 2028, which includes a swingline sub-limit of at least $5,000 and a letter of credit sub-limit of at least $5,000. The new Capital One Credit Facility was entered into with Capital One, N.A., acting as administrative agent and replaced our previous senior secured revolving credit facility with SVB. The Capital One Credit Facility will give the Company additional financial flexibility, through the facility’s five year term. The facility is available to the Company for working capital and general corporate purposes. The Capital One Credit Facility bears interest at a rate per annum based on the Secured Overnight Financing Rate (“SOFR”) or a Base Rate as specified in the Credit Agreement. As of January 31, 2024, the interest rate on the Capital One Credit Facility was 8.3%. In addition to principal and interest due under the Capital One Credit Facility, the Company is required to pay an annual fee equal to 0.25% of the unused balance of the facility. Additionally, the Company incurred creditor and third party fees of $778 upon entering into the Capital One Credit Facility. The Company recorded the fees to deferred financing costs, included within other assets on its consolidated balance sheets, and will amortize the costs over the term of the Capital One Credit Facility. The obligations under the Capital One Credit Facility are secured by a first priority security interest in substantially all of the tangible and intangible assets at certain of the Company's U.S. subsidiaries, and by pledges of the equity of certain of the Company's U.S. subsidiaries, in each case subject to customary exclusions. The Capital One Credit Facility includes financial covenants including, but not limited to requiring the Company to maintain minimum Consolidated EBITDA, minimum Liquidity, a minimum Consolidated Fixed Charge Coverage Ratio a restriction on the amount of dividends and limiting the amount of cash and cash equivalents the Company holds outside Capital One, each as defined in the Credit Agreement. Maturities of finance leases and other debt in each of the next five years and thereafter are as follows: Total Finance Leases Other Debt Fiscal year ending January 31, 2025 $ 6,056 $ 4,958 $ 1,098 2026 4,167 2,837 1,330 2027 1,233 514 719 Total maturities of finance leases and other debt $ 11,456 $ 8,309 $ 3,147 The following table presents the components of interest income (expense), net: Fiscal years ended January 31, 2024 2023 2022 Interest expense (1) $ (1,854) $ (1,411) $ (1,163) Interest income 4,065 2,475 79 Interest income (expense), net $ 2,211 $ 1,064 $ (1,084) (1) Includes amortization of deferred financing costs and original issue discount

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Jan. 31, 2024
Equity [Abstract]
Stockholders' Equity	Stockholders' Equity (a) Common stock The Company closed an IPO on July 22, 2019 and filed an Amended and Restated Certificate of Incorporation authorizing the issuance of up to 500,000,000 shares of common stock, par value $0.01 per share. On April 12, 2021, the Company completed a follow-on offering of its common stock. In connection with this offering, the Company issued and sold 5,175,000 shares of common stock at an issuance price of $50.00 per share. In connection with the MediFind Acquisition, on June 30, 2023, the Company issued 150,786 shares of common stock, par value $0.01 per share, to the former owners of MediFind as partial consideration to acquire MediFind. On July 3, 2023, the Company filed a prospectus supplement to register the shares with the SEC. See Note 16 - Acquisitions for additional information regarding the MediFind Acquisition. In connection with the Access Acquisition, on August 11, 2023, the Company issued 1,096,436 shares of common stock, par value $0.01 per share, to the former members of Access as partial consideration to acquire Access. On August 14, 2023, the Company filed a prospectus supplement to register the shares with the SEC. See Note 16 - Acquisitions for additional information regarding the Access Acquisition. (b) Treasury stock The Company's equity-based compensation plan allows for the grant of non-vested stock options, RSUs and total shareholder return ("TSR") performance-based stock units ("PSUs") to its employees pursuant to the terms of its stock option and incentive plans (See Note 8). Until September 2023, under the provision of the plans, for RSU and PSU awards, unless otherwise elected, employee participants fulfilled their related income tax withholding obligation by having shares withheld at the time of vesting. The shares withheld were then transferred to the Company's treasury stock at cost. Beginning in September 2023, employee participants fulfilled their related tax withholding obligation by selling vested shares at the time of vesting in non-discretionary transactions pursuant to the Company’s mandatory sell-to-cover policy (sell-to-cover). The proceeds from the employee participants’ sales of vested shares are remitted to the Company to cover the tax withholding payments to tax authorities. No shares are transferred to the Company’s treasury stock in connection with tax withholdings funded by an employee participant’s sale of vested shares to cover taxes.

Equity-based compensation

Equity-based compensation	12 Months Ended
	Jan. 31, 2024
Share-Based Payment Arrangement [Abstract]
Equity-based compensation	Equity-based compensation (a) Equity award plans In January 2018, the Board of Directors adopted the Company’s 2018 Stock Option Plan as amended, (the "2018 Stock Option Plan") which provided for the issuance of options to purchase up to 3,048,490 shares of the Company’s common stock to officers, directors, employees, and consultants. The option exercise price per share is determined by the Board of Directors based on the estimated fair value of the Company’s common stock. In June 2019, the Board of Directors adopted the Company’s 2019 Stock Option and Incentive Plan (the "2019 Plan"), which replaced the 2018 Stock Option Plan upon the completion of the IPO. The 2019 Plan allows the Compensation Committee of the Board of Directors (the "Compensation Committee") to make equity-based incentive awards including stock options, RSUs and PSUs to the Company’s officers, employees, directors, and consultants. The initial reserve for the issuance of awards under this plan was 2,139,683 shares of common stock. The initial number of shares reserved and available for issuance automatically increased on February 1, 2020 and automatically increases each February 1 thereafter by 5% of the number of shares of common stock outstanding on the immediately preceding January 31 (or such lesser number of shares determined by the Compensation Committee). As the 2018 Stock Option Plan was replaced by the 2019 Plan, all grants of stock options, RSUs and PSUs during the years ended January 31, 2024, 2023 and 2022 were made pursuant to the 2019 plan, respectively. In June 2019, the Board of Directors also adopted the Company's 2019 Employee Stock Purchase Plan (the "ESPP"), which became effective immediately prior to the effectiveness of the registration statement for the Company’s initial public offering. The total shares of common stock initially reserved under the ESPP was limited to 855,873 shares. The Company's incentive bonuses allow eligible employees to elect to receive all or a portion of their incentive compensation in the form of immediately vested restricted stock units instead of cash. In July 2023, the Board of Directors also adopted the Inducement Plan. The Inducement Plan allows the Compensation Committee of the Board of Directors (the "Compensation Committee") or its delegates to make equity-based incentive awards including certain stock options, RSUs and PSUs to employees of acquired companies to induce them to join the Company. The total shares of common stock initially reserved under the Inducement Plan was 500,000 shares. As of January 31, 2024, there are 4,303,135 shares available for future grant pursuant to the 2019 Plan after factoring in the automatic increase which occurs on February 1 of each fiscal year, as well as an additional 418,434 shares available for future grant pursuant to the ESPP. The ESPP has two six-month offering periods each calendar year beginning in January and July. The ESPP allows eligible employees to purchase shares of the Company’s common stock at a 15% discount through payroll deductions. As of January 31, 2024, there were 24,125 outstanding restricted stock units and 475,875 shares available for future grant under the Inducement Plan. (b) Summary of stock-based compensation The following table sets forth stock-based compensation by type of award: For the fiscal years ended 2024 2023 2022 RSUs $ 53,474 $ 42,214 $ 24,222 Liability awards 9,047 7,641 7,055 PSUs 9,206 7,282 2,389 Stock options 45 1,489 2,294 ESPP 1,256 1,521 763 Total stock-based compensation $ 73,028 $ 60,147 $ 36,723 The following table sets forth the presentation of stock-based compensation in the Company's consolidated financial statements: For the fiscal years ended 2024 2023 2022 Stock-based compensation expense recorded to additional paid-in capital (1) $ 63,981 $ 52,506 $ 29,668 Stock-based compensation expense recorded to accrued expenses 9,047 7,641 7,055 Total stock-based compensation 73,028 60,147 36,723 Less: stock-based compensation expense capitalized as internal-use software (1,415) (1,372) (489) Stock-based compensation expense per consolidated statements of operations (2) $ 71,613 $ 58,775 $ 36,234 (1) Stock-based compensation included in the Company's consolidated statements of stockholders' equity is consistent with these amounts. (2) Non-cash stock-based compensation expense included in the Company's consolidated statements of cash flows for the fiscal year ended January 31, 2022 was $36,144, and excluded $90 of cash-settled stock-based compensation expense included in the Company's statements of operations. The Company has not recognized and does not expect to recognize in the foreseeable future, any tax benefit related to employee stock-based compensation expense. (c) Restricted stock units The Company has issued restricted stock units to employees and independent directors that vest based on a time-based condition. For RSUs granted to employees prior to January 2021, pursuant to a time-based condition, 10% of the restricted stock units vest after one year, 20% vest after two years, 30% vest after three years and 40% vest after four years. The restricted stock units expire seven years from the grant date. During the year ended January 31, 2023, the Company modified the vesting of RSUs granted subsequent to January 1, 2021 for employees other than its named executive officers listed in its 2022 proxy statement ("2022 NEOs") and other members of its executive management team. Pursuant to the modified vesting schedule, RSUs granted after January 1, 2021 for employees other than 2022 NEOs and other members of its executive management team, vest 6.25% each quarter over four years based on continued service. For 2022 NEOs and other members of the Company's executive management team, RSUs granted from January 1, 2022 through December 31, 2022 vest 6.25% each quarter over four years based on continued service. Beginning January 2023, all RSUs granted vest 25% each year over four years based on continued service. Additionally, at the beginning of each fiscal year, the Company provides certain employees the option to settle their incentive bonus in immediately vested RSUs. RSUs granted to settle bonus awards are included in RSUs granted and vested in the table below. See section (g) Liability awards below for additional information regarding share-settled bonus awards. Restricted stock units Unvested, January 31, 2021 2,053,038 Granted during year 1,836,534 Vested (559,767) Forfeited and expired (195,966) Unvested, January 31, 2022 3,133,839 Granted during year 2,907,838 Vested (1,626,679) Forfeited and expired (497,245) Unvested, January 31, 2023 3,917,753 Granted during year (1) 2,419,679 Vested (1,912,432) Forfeited and expired (624,790) Unvested, January 31, 2024 3,800,210 (1) Includes 24,125 awards granted pursuant to the 2023 Inducement Award Plan. As of January 31, 2024, there is $100,100 remaining of total unrecognized compensation costs related to these awards. The total unrecognized costs are expected to be recognized over a weighted-average term of 2.6 years. For the years ended January 31, 2024, 2023 and 2022, the weighted average grant date fair value of restricted stock units granted was $29.08, $26.79 and $46.60 respectively. (d) Stock options Options granted under the equity award plans have a maximum term of ten years and vest over a period determined by the Board of Directors (generally four years from the date of grant or the commencement of the grantee’s employment with the Company). Options generally vest 25% at the one-year anniversary of the grant date, after which point they generally vest pro rata on a monthly basis. Stock option activity for the fiscal years ended January 31, 2024, 2023 and 2022 is as follows: Number of Weighted- Weighted- Aggregate Intrinsic Outstanding — January 31, 2021 3,211,354 $ 4.67 Granted during the year — $ — Exercised (1,439,186) $ 2.88 Forfeited (67,018) $ 9.02 Outstanding and expected to vest — January 31, 2022 1,705,150 $ 6.01 5.94 $ 42,938 Outstanding — January 31, 2022 1,705,150 $ 6.01 Granted during the year — $ — Exercised (311,743) $ 4.92 Forfeited and expired (8,214) $ 4.68 Outstanding and expected to vest — January 31, 2023 1,385,193 $ 6.26 5.06 $ 43,341 Outstanding — January 31, 2023 1,385,193 $ 6.26 Granted during the year — $ — Exercised (249,247) $ 3.42 Forfeited and expired (12,508) $ 5.87 Outstanding and expected to vest — January 31, 2024 1,123,438 $ 6.89 4.54 $ 20,884 Exercisable — January 31, 2024 1,123,438 $ 6.89 4.54 $ 20,884 Amount vested during year ended January 31, 2024 24,565 $ 13.41 The aggregate intrinsic value represents the total pre-tax intrinsic value (the difference between the Company’s estimated stock price at the time of exercise and the exercise price, multiplied by the number of related in-the-money options) that would have been received by the option holders had they exercised their options at the end of the period. This amount changes based on the market value of the Company’s common stock. The total intrinsic value of options exercised for the years ended January 31, 2024, 2023 and 2022 (based on the difference between the Company’s estimated stock price on the exercise date and the respective exercise price, multiplied by the number of options exercised), was $6,059, $6,970 and $73,624, respectively. As of January 31, 2024, all compensation cost related to stock options issued to employees has been recorded and there is no unrecognized compensation cost remaining related to stock options issued to employees. (e) TSR performance-based restricted stock units ("PSUs") The Company grants PSUs to certain members of its management team. PSUs vest over approximately three years from the grant date upon satisfaction of both time-based requirements and market targets based on Phreesia's TSR relative to the TSR of each member of the Russell 3000 Index (the "Peer Group"). Depending on the percentage level at which the market-based condition is satisfied, the number of shares vesting could be between 0% and 220% of the number of PSUs originally granted. PSUs granted during the years ended January 31, 2024, 2023 and 2022 vest in a maximum of 220%, 200% and 200% of the number of PSUs originally granted, respectively. To earn the target number of PSUs (which represents 100% of the number of PSUs granted), the Company must perform at the 60th percentile, with the maximum number of PSUs earned if the Company performed at least at the 90th percentile. If Phreesia's TSR for the performance period is negative, the maximum number of PSUs that can be earned will be capped at 100%. The Company estimated the fair value of the PSUs using a Monte Carlo Simulation model which projected TSR for Phreesia and each member of the Peer Group over the performance period. The Company recognizes the grant date fair value of PSUs as compensation expense over the vesting period. The fair value of the PSUs granted during the fiscal years ended January 31, 2024, 2023 and 2022, respectively, was estimated using the following assumptions: Fiscal years ended January 31, 2024 2023 2022 Correlation coefficient 0.5238 0.4957 0.3878 Valuation date stock price $ 22.94 $ 35.41 $ 36.03 Simulation term 3.00 Years 3.00 Years 2.99 Years Volatility 64.58 % 64.98 % 44.32 % Risk-free rate 4.05 % 3.84 % 1.23 % Dividend yield — % — % — % Weighted average fair value of grants $ 36.42 $ 56.52 $ 48.47 Performance Outstanding, February 1, 2021 70,806 Granted during the year ended January 31, 2022 325,410 Outstanding, February 1, 2022 396,216 Granted during the year ended January 31, 2023 255,572 Vested — Forfeited and expired (3,555) Outstanding, February 1, 2023 648,233 Granted during the year ended January 31, 2024 576,680 Vested (67,251) Forfeited (117,443) Outstanding, January 31, 2024 1,040,219 As of January 31, 2024, unrecognized compensation cost for the PSUs was $32,077, to be recognized over a weighted average remaining vesting period of 2.4 years, subject to the participants' continued employment with the Company. (f) Employee stock purchase plan The ESPP is a compensatory plan because it provides participants with terms that are more favorable than those offered to other holders of the Company's common stock. Employees purchase shares at the lesser of (1) 85% of the closing stock price on the first day of the offering period or (2) 85% of the closing stock price on the last day of the offering period. The ESPP is structured as a qualified employee stock purchase plan under Section 423 of the U.S. Internal Revenue Code of 1986. The fair value of shares granted under the ESPP during the year ended January 31, 2024 was estimated using a Black-Scholes pricing model with the following assumptions: Year ended Year ended Year ended Risk-free interest rate 5.30 % 3.68 % 0.17 % Expected dividends none none none Expected term (in years) 0.49 years 0.47 years 0.49 years Volatility 62.4 % 74.8 % 55.7 % As of January 31, 2024, unrecognized compensation cost related to the ESPP was $616, to be recognized over the next five months. (g) Liability awards At the beginning of each year, the Company provides eligible employees the option to elect to receive all or a portion of their incentive compensation in the form of immediately vested restricted stock units instead of cash. Restricted stock units issued to settle liability awards are covered by the 2019 Plan. Share-settled bonus awards will be settled at a value equal to 115% of the bonuses converted. These share-settled bonus awards vest based on the achievement of the Company’s predefined performance targets. As share-settled bonus awards will be settled in a variable number of shares, the Company classifies share-settled bonus awards as liabilities, within accrued expenses in the accompanying consolidated balance sheets until they are settled in shares and included in stockholders' equity. The Company's share-settled bonus awards are settled semiannually. During the year-ended January 31, 2024, the Company settled $9,041 of share-settled bonus awards by issuing 354,817 immediately vested RSUs. See (c) Restricted Stock Units above for additional discussion regarding RSUs.

Fair value measurements

Fair value measurements	12 Months Ended
	Jan. 31, 2024
Fair Value Disclosures [Abstract]
Fair value measurements	Fair value measurements The following table presents information about the Company's assets and liabilities that are measured at fair value as of January 31, 2024 and indicates the classification of each item within the fair value hierarchy: Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Balance as of January 31, 2024 Money market mutual funds $ 58,942 $ — $ — $ 58,942 Total assets $ 58,942 $ — $ — $ 58,942 The following table presents information about the Company's assets and liabilities that are measured at fair value as of January 31, 2023 and indicates the classification of each item within the fair value hierarchy: Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Balance as of January 31, 2023 Money market mutual funds $ 163,563 $ — $ — $ 163,563 Total assets $ 163,563 $ — $ — $ 163,563 The carrying value of the Company’s short-term financial instruments, including accounts receivable and accounts payable approximate fair value due to the short-term nature of these instruments. As of January 31, 2024, the carrying value of the Company's debt and deferred consideration liabilities approximate fair value because the interest rates approximate market rates and their maturities are relatively short-term. The Company did not have any transfers of assets and liabilities between levels of the fair value measurement hierarchy during both the years ended January 31, 2024 and 2023.

Leases

Leases	12 Months Ended
	Jan. 31, 2024
Leases [Abstract]
Leases	Leases (a) Phreesia as Lessee The Company leases office premises and third-party data center space in the U.S under operating leases which expire on various dates through March 2027. Certain of these arrangements have escalating rent payment provisions or optional renewal clauses. The table below only considers lease obligations through the renewal date as the Company is not reasonably certain to elect the option to extend its leases beyond the option date. No arrangements contain residual value guarantees or restrictions imposed on the leases. The Company is also committed to pay a portion of the actual operating expenses under certain of these lease agreements. These operating expenses are not included in the table below. The Company has also entered into various finance lease arrangements for computer equipment. These agreements are typically for two During the year ended January 31, 2023, the Company ceased using its office premises in Ottawa, Canada and Raleigh, North Carolina. Additionally, during the year ended January 31, 2023, the Company decided to cease using its office premise in Portland, Oregon by April 2023. In connection with these decisions, the Company shortened the useful lives of the related right of use assets to end on the cease use date for each lease. The financial impact of the change in useful lives of the related right of use assets was not significant. Supplemental balance sheet information related to operating and finance leases as of January 31, 2024 and 2023 was as follows: January 31, 2024 2023 Operating leases: Lease right-of-use assets $ 266 $ 569 Lease liabilities, current $ 393 $ 934 Lease liabilities, non-current 134 349 Total operating lease liabilities $ 527 $ 1,283 Finance leases: Property and equipment, at cost $ 35,250 $ 27,813 Accumulated depreciation (27,399) (20,657) Property and equipment, net $ 7,851 $ 7,156 Lease liabilities, current (included in Current portion of finance lease liabilities and other debt) 4,958 4,926 Lease liabilities, non-current (included in Long-term finance lease liabilities and other debt) 3,351 2,725 Total finance lease liabilities $ 8,309 $ 7,651 For office leases and leased equipment, the Company has elected the practical expedient to not separate lease and non-lease components, and as such, the variable lease cost primarily represents variable payments such as common area maintenance, utilities and equipment maintenance. As of January 31, 2024, for operating leases, the weighted-average remaining lease term is 1.3 years and the weighted-average discount rate is 5.0%. As of January 31, 2024, for finance leases, the weighted-average remaining lease term is 1.8 years and the weighted-average discount rate is 6.3%. The components of lease expense for the years ended January 31, 2024, 2023 and 2022 were as follows: Fiscal years ended 2024 2023 2022 Operating leases: Operating lease cost $ 740 $ 1,835 $ 1,096 Variable lease cost 47 62 223 Total operating lease cost $ 787 $ 1,897 $ 1,319 Finance leases: Amortization of right-of-use assets $ 6,742 $ 5,632 $ 4,636 Interest on lease liabilities 580 368 378 Total finance lease cost $ 7,322 $ 6,000 $ 5,014 Amortization of right-of-use assets for finance leases is included within depreciation expense on the Company's consolidated statements of operations. The following represents a schedule of maturing lease commitments for operating and finance leases as of January 31, 2024: January 31, 2024 Operating Finance Maturity of lease liabilities Fiscal year ending January 31, 2025 $ 404 $ 5,343 2026 86 2,986 2027 42 521 2028 7 — Total future minimum lease payments $ 539 $ 8,850 Less: interest (12) (541) Present value of lease liabilities $ 527 $ 8,309 As of January 31, 2024, the Company has signed a finance lease for computer equipment which does not commence until April 2024. Total undiscounted payments through the fiscal year ended January 31, 2028, related to the lease are $7,413 and are excluded from the table above but are included in the Company's other contractual commitments. See Note 11 - Commitments and contingencies for additional information regarding other contractual commitments. Other supplemental cash flow information for the years ended January 31, 2024, 2023 and 2022 was as follows: Fiscal years ended 2024 2023 2022 Supplemental cash flow information Cash paid for amounts included in the measurement of lease liabilities: Operating cash used for operating leases $ 1,238 $ 1,347 $ 1,206 Operating cash used for finance leases 535 396 377 Financing cash used for finance leases 6,779 5,731 4,267 (b) Phreesia as Lessor In connection with the patient intake and registration process, Phreesia offers its customers the ability to lease PhreesiaPads and Arrivals Kiosks along with their monthly subscription. These rentals fall under the guidance of ASC 842. The Company elected the practical expedient to not separate lease and non-lease components. More specifically, all contractual hardware maintenance is included with the hardware lease components. The leases contain no variable lease payments, no options to extend the lease that are reasonably certain to be exercised, and do not give the lessee an option to purchase the hardware at the end of the lease term. Additionally, the lease term does not represent a major part of the remaining economic life of the assets, and the present value of the lease payments does not equal or exceed substantially all of the fair value of the assets. As a result, all leased hardware in the SaaS arrangements is classified as operating leases. During the years ended January 31, 2024, 2023 and 2022, the Company recognized $10,307, $10,197 and $6,489, respectively in subscription and related services revenue related to the leasing of PhreesiaPads and Arrivals Kiosks.
Leases	Leases (a) Phreesia as Lessee The Company leases office premises and third-party data center space in the U.S under operating leases which expire on various dates through March 2027. Certain of these arrangements have escalating rent payment provisions or optional renewal clauses. The table below only considers lease obligations through the renewal date as the Company is not reasonably certain to elect the option to extend its leases beyond the option date. No arrangements contain residual value guarantees or restrictions imposed on the leases. The Company is also committed to pay a portion of the actual operating expenses under certain of these lease agreements. These operating expenses are not included in the table below. The Company has also entered into various finance lease arrangements for computer equipment. These agreements are typically for two During the year ended January 31, 2023, the Company ceased using its office premises in Ottawa, Canada and Raleigh, North Carolina. Additionally, during the year ended January 31, 2023, the Company decided to cease using its office premise in Portland, Oregon by April 2023. In connection with these decisions, the Company shortened the useful lives of the related right of use assets to end on the cease use date for each lease. The financial impact of the change in useful lives of the related right of use assets was not significant. Supplemental balance sheet information related to operating and finance leases as of January 31, 2024 and 2023 was as follows: January 31, 2024 2023 Operating leases: Lease right-of-use assets $ 266 $ 569 Lease liabilities, current $ 393 $ 934 Lease liabilities, non-current 134 349 Total operating lease liabilities $ 527 $ 1,283 Finance leases: Property and equipment, at cost $ 35,250 $ 27,813 Accumulated depreciation (27,399) (20,657) Property and equipment, net $ 7,851 $ 7,156 Lease liabilities, current (included in Current portion of finance lease liabilities and other debt) 4,958 4,926 Lease liabilities, non-current (included in Long-term finance lease liabilities and other debt) 3,351 2,725 Total finance lease liabilities $ 8,309 $ 7,651 For office leases and leased equipment, the Company has elected the practical expedient to not separate lease and non-lease components, and as such, the variable lease cost primarily represents variable payments such as common area maintenance, utilities and equipment maintenance. As of January 31, 2024, for operating leases, the weighted-average remaining lease term is 1.3 years and the weighted-average discount rate is 5.0%. As of January 31, 2024, for finance leases, the weighted-average remaining lease term is 1.8 years and the weighted-average discount rate is 6.3%. The components of lease expense for the years ended January 31, 2024, 2023 and 2022 were as follows: Fiscal years ended 2024 2023 2022 Operating leases: Operating lease cost $ 740 $ 1,835 $ 1,096 Variable lease cost 47 62 223 Total operating lease cost $ 787 $ 1,897 $ 1,319 Finance leases: Amortization of right-of-use assets $ 6,742 $ 5,632 $ 4,636 Interest on lease liabilities 580 368 378 Total finance lease cost $ 7,322 $ 6,000 $ 5,014 Amortization of right-of-use assets for finance leases is included within depreciation expense on the Company's consolidated statements of operations. The following represents a schedule of maturing lease commitments for operating and finance leases as of January 31, 2024: January 31, 2024 Operating Finance Maturity of lease liabilities Fiscal year ending January 31, 2025 $ 404 $ 5,343 2026 86 2,986 2027 42 521 2028 7 — Total future minimum lease payments $ 539 $ 8,850 Less: interest (12) (541) Present value of lease liabilities $ 527 $ 8,309 As of January 31, 2024, the Company has signed a finance lease for computer equipment which does not commence until April 2024. Total undiscounted payments through the fiscal year ended January 31, 2028, related to the lease are $7,413 and are excluded from the table above but are included in the Company's other contractual commitments. See Note 11 - Commitments and contingencies for additional information regarding other contractual commitments. Other supplemental cash flow information for the years ended January 31, 2024, 2023 and 2022 was as follows: Fiscal years ended 2024 2023 2022 Supplemental cash flow information Cash paid for amounts included in the measurement of lease liabilities: Operating cash used for operating leases $ 1,238 $ 1,347 $ 1,206 Operating cash used for finance leases 535 396 377 Financing cash used for finance leases 6,779 5,731 4,267 (b) Phreesia as Lessor In connection with the patient intake and registration process, Phreesia offers its customers the ability to lease PhreesiaPads and Arrivals Kiosks along with their monthly subscription. These rentals fall under the guidance of ASC 842. The Company elected the practical expedient to not separate lease and non-lease components. More specifically, all contractual hardware maintenance is included with the hardware lease components. The leases contain no variable lease payments, no options to extend the lease that are reasonably certain to be exercised, and do not give the lessee an option to purchase the hardware at the end of the lease term. Additionally, the lease term does not represent a major part of the remaining economic life of the assets, and the present value of the lease payments does not equal or exceed substantially all of the fair value of the assets. As a result, all leased hardware in the SaaS arrangements is classified as operating leases. During the years ended January 31, 2024, 2023 and 2022, the Company recognized $10,307, $10,197 and $6,489, respectively in subscription and related services revenue related to the leasing of PhreesiaPads and Arrivals Kiosks.
Leases	Leases (a) Phreesia as Lessee The Company leases office premises and third-party data center space in the U.S under operating leases which expire on various dates through March 2027. Certain of these arrangements have escalating rent payment provisions or optional renewal clauses. The table below only considers lease obligations through the renewal date as the Company is not reasonably certain to elect the option to extend its leases beyond the option date. No arrangements contain residual value guarantees or restrictions imposed on the leases. The Company is also committed to pay a portion of the actual operating expenses under certain of these lease agreements. These operating expenses are not included in the table below. The Company has also entered into various finance lease arrangements for computer equipment. These agreements are typically for two During the year ended January 31, 2023, the Company ceased using its office premises in Ottawa, Canada and Raleigh, North Carolina. Additionally, during the year ended January 31, 2023, the Company decided to cease using its office premise in Portland, Oregon by April 2023. In connection with these decisions, the Company shortened the useful lives of the related right of use assets to end on the cease use date for each lease. The financial impact of the change in useful lives of the related right of use assets was not significant. Supplemental balance sheet information related to operating and finance leases as of January 31, 2024 and 2023 was as follows: January 31, 2024 2023 Operating leases: Lease right-of-use assets $ 266 $ 569 Lease liabilities, current $ 393 $ 934 Lease liabilities, non-current 134 349 Total operating lease liabilities $ 527 $ 1,283 Finance leases: Property and equipment, at cost $ 35,250 $ 27,813 Accumulated depreciation (27,399) (20,657) Property and equipment, net $ 7,851 $ 7,156 Lease liabilities, current (included in Current portion of finance lease liabilities and other debt) 4,958 4,926 Lease liabilities, non-current (included in Long-term finance lease liabilities and other debt) 3,351 2,725 Total finance lease liabilities $ 8,309 $ 7,651 For office leases and leased equipment, the Company has elected the practical expedient to not separate lease and non-lease components, and as such, the variable lease cost primarily represents variable payments such as common area maintenance, utilities and equipment maintenance. As of January 31, 2024, for operating leases, the weighted-average remaining lease term is 1.3 years and the weighted-average discount rate is 5.0%. As of January 31, 2024, for finance leases, the weighted-average remaining lease term is 1.8 years and the weighted-average discount rate is 6.3%. The components of lease expense for the years ended January 31, 2024, 2023 and 2022 were as follows: Fiscal years ended 2024 2023 2022 Operating leases: Operating lease cost $ 740 $ 1,835 $ 1,096 Variable lease cost 47 62 223 Total operating lease cost $ 787 $ 1,897 $ 1,319 Finance leases: Amortization of right-of-use assets $ 6,742 $ 5,632 $ 4,636 Interest on lease liabilities 580 368 378 Total finance lease cost $ 7,322 $ 6,000 $ 5,014 Amortization of right-of-use assets for finance leases is included within depreciation expense on the Company's consolidated statements of operations. The following represents a schedule of maturing lease commitments for operating and finance leases as of January 31, 2024: January 31, 2024 Operating Finance Maturity of lease liabilities Fiscal year ending January 31, 2025 $ 404 $ 5,343 2026 86 2,986 2027 42 521 2028 7 — Total future minimum lease payments $ 539 $ 8,850 Less: interest (12) (541) Present value of lease liabilities $ 527 $ 8,309 As of January 31, 2024, the Company has signed a finance lease for computer equipment which does not commence until April 2024. Total undiscounted payments through the fiscal year ended January 31, 2028, related to the lease are $7,413 and are excluded from the table above but are included in the Company's other contractual commitments. See Note 11 - Commitments and contingencies for additional information regarding other contractual commitments. Other supplemental cash flow information for the years ended January 31, 2024, 2023 and 2022 was as follows: Fiscal years ended 2024 2023 2022 Supplemental cash flow information Cash paid for amounts included in the measurement of lease liabilities: Operating cash used for operating leases $ 1,238 $ 1,347 $ 1,206 Operating cash used for finance leases 535 396 377 Financing cash used for finance leases 6,779 5,731 4,267 (b) Phreesia as Lessor In connection with the patient intake and registration process, Phreesia offers its customers the ability to lease PhreesiaPads and Arrivals Kiosks along with their monthly subscription. These rentals fall under the guidance of ASC 842. The Company elected the practical expedient to not separate lease and non-lease components. More specifically, all contractual hardware maintenance is included with the hardware lease components. The leases contain no variable lease payments, no options to extend the lease that are reasonably certain to be exercised, and do not give the lessee an option to purchase the hardware at the end of the lease term. Additionally, the lease term does not represent a major part of the remaining economic life of the assets, and the present value of the lease payments does not equal or exceed substantially all of the fair value of the assets. As a result, all leased hardware in the SaaS arrangements is classified as operating leases. During the years ended January 31, 2024, 2023 and 2022, the Company recognized $10,307, $10,197 and $6,489, respectively in subscription and related services revenue related to the leasing of PhreesiaPads and Arrivals Kiosks.

Commitments and contingencies

Commitments and contingencies	12 Months Ended
	Jan. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	Commitments and contingencies (a) Indemnifications The Company’s agreements with certain customers include certain provisions for indemnifying customers against liabilities if its services infringe a third-party’s intellectual property rights. It is not possible to determine the maximum potential amount under these indemnification obligations due to the limited history of prior indemnification claims and the unique facts and circumstances that may be involved in each particular agreement. To date, the Company has not incurred any material costs as a result of such provisions and have not accrued a ny liabilities related to such obligations in its consolidated financial statements. In addition, the Company has indemnification agreements with its directors and its executive officers that require it, among other things, to indemnify its directors and executive officers for costs associated with any fees, expenses, judgments, fines and settlement amounts incurred by any of those persons in any action or proceedi n g to which any of those persons is, or is threatened to be, made a party by reason of the person’s service as a director or officer, including any action by us, arising out of that person’s services as a director or officer or that person’s services provided to any other company or enterprise at the Company’s request. The Company maintains director and officer insurance coverage that may enable it to recover a portion of any future indemnification amounts paid. To date, there have been no claims under any of its directors and executive officers indemnification provisions. (b) Legal proceedings In the ordinary course of business, the Company may be subject from time to time to various proceedings, lawsuits, disputes or claims. Although the Company cannot predict with assurance the outcome of any litigation, the Company does not believe there are currently any such actions that, if resolved unfavorably, would have a material impact on its financial condition, results of operations or cash flows. (c) Other contractual commitments Other contractual commitments consist primarily of non-cancelable purchase commitments to support our technology infrastructure as well as installment payments for deferred consideration payable in connection with the acquisition of ConnectOnCall. Future minimum payments under our non-cancelable contractual commitments as of January 31, 2024 are presented in the table below. Purchase obligations Fiscal year ending January 31, 2025 $ 15,067 2026 9,171 2027 4,520 2028 2,260 Total $ 31,018

Income taxes

Income taxes	12 Months Ended
	Jan. 31, 2024
Income Tax Disclosure [Abstract]
Income taxes	Income taxes The Company recorded a tax provision of $1,543, $483 and $182, for the years ended January 31, 2024, 2023 and 2022, respectively. The Company's provision for income taxes was 1.1%, 0.3% and 0.2% of loss before income taxes for the years ended January 31, 2024, 2023 and 2022, respectively. The Company's effective tax rate differs from the U.S. statutory tax rate of 21% primarily because the Company records a valuation allowance against the its U.S. deferred tax assets, and due to foreign income tax expense related to its Canadian branch. Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. Management of the Company has evaluated the positive and negative evidence pertaining to the realizability of its deferred tax assets, including the Company’s history of losses, and concluded that it is more likely than not that the Company will not recognize the benefits for the majority of its deferred tax assets. On the basis of this evaluation, the Company has recorded a valuation allowance against its deferred tax assets that are not more likely than not to be realized at both January 31, 2024 and 2023. The Company’s loss before income taxes was primarily generated in the United States for fiscal 2024, 2023 and 2022. The Company's income tax provision consisted of the following for fiscal 2024, 2023 and 2022: Fiscal years ended January 31, 2024 2023 2022 Current tax Federal $ — $ — $ — State 76 49 39 Foreign 1,239 — — Deferred tax Federal 38 109 — State — — — Foreign 190 325 143 Total provision for income taxes $ 1,543 $ 483 $ 182 A reconciliation of the statutory U.S. federal income tax rate to the Company's effective tax rate for fiscal 2024, 2023 and 2022 is as follows: Fiscal years ended January 31, 2024 2023 2022 Federal income tax benefit at statutory rate 21 % 21 % 21 % State and local tax, net of federal benefit 3 % 5 % 9 % Permanent differences — % — % — % Equity compensation — % — % 6 % Foreign taxes (1) % — % — % Other — % — % — % Change in valuation allowance (24) % (26) % (36) % Effective income tax rate (1) % — % — % The significant components of the Company's deferred income tax assets and liabilities as of January 31, 2024 and 2023 are as follows: January 31, Deferred tax (liabilities) assets 2024 2023 Net operating loss carryforwards $ 160,791 $ 131,574 Stock based compensation 9,278 7,765 Accruals, reserves, and other expenses 3,668 2,763 Reserve for bad debts 793 530 Disallowed interest expense 1,041 1,934 Depreciation and amortization 1,829 — Total deferred tax assets 177,400 144,566 Less: valuation allowance (176,641) (143,135) Net deferred tax (liabilities) assets 759 1,431 Depreciation and amortization — (295) Intangible assets (569) (305) Deferred contract acquisition costs (460) (750) Total deferred tax liabilities (1,029) (1,350) Net deferred tax (liabilities) assets $ (270) $ 81 The Company has accumulated a U.S. Federal net operating loss carryforward of approximately $598,975 and $493,333 as of January 31, 2024 and 2023, respectively. This carryforward may be available to offset future U.S. Federal income tax liabilities and will expire beginning in 2025. As of January 31, 2024, the Company's foreign branch had no net operating loss carryforwards. The Company utilized the net operating loss carryforwards related to its foreign branch to offset taxable income in Canada during the year ended January 31, 2024. The Company’s unutilized research and development tax credit carryforwards may be carried forward for a period of up to 20 years. Due to the uncertainty regarding the ability to realize the benefit of the U.S. deferred tax assets primarily relating to net operating loss carryforwards, valuation allowances have been established to reduce the U.S. deferred tax assets to an amount that is more likely than not to be realized. On the basis of this evaluation, as of January 31, 2024 and 2023, the Company recorded a valuation allowance of $176,641 and $143,135, respectively, to recognize only the portion of the deferred tax asset that is more likely than not to be realized. The $33,506 increase in the valuation allowance recorded during the fiscal year ended January 31, 2024 relates primarily to deferred tax assets established and recorded during the fiscal year ended January 31, 2024. The amount of the deferred tax asset considered realizable, however, could be adjusted if estimates of future taxable foreign income during the carryforward period are reduced. Under Section 382 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an “ownership change” (generally defined as a greater than 50% change by value in its equity ownership over a three-year period), the corporation’s ability to use its pre-ownership change net operating loss carryforwards and other pre-ownership change tax attributes to offset its post-change income may be limited. As of January 31, 2024, the Company has U.S. net operating loss carryforwards of approximately $599.0 million. The Company has completed a Section 382 study and as a result of the analysis, it is more likely than not that the Company has experienced an “ownership change”. The Company may also experience ownership changes in the future as a result of subsequent shifts in its stock ownership. Accordingly, if the Company earns net taxable income, it is more likely than not that the Company's ability to use its pre-ownership change net operating loss carryforwards to offset U.S. federal taxable income will be subject to limitations, which could potentially result in increased future tax liability. The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal, state, and foreign jurisdictions, where applicable. The Company’s tax years are still open from 2019 to present and, to the extent utilized in future years' tax returns, net operating loss carryforwards at January 31, 2024 will remain subject to examination until the respective tax year is closed. The Company records unrecognized tax benefits as liabilities or as reductions to deferred tax assets in accordance with ASC 740 and adjusts these balances when its judgement changes as a result of the evaluation of new information previously not available. The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. As of January 31, 2024 the Company has reduced the balance of deferred tax assets for $1.2 million of unrecognized tax benefits. The Company’s unrecognized tax benefits would not affect the effective tax rate if recognized because the Company has a full valuation allowance on its U.S. deferred tax assets. As of January 31, 2024, the Company had no accrued interest or penalties related to uncertain tax positions. The following is a roll-forward of the Company's total gross unrecognized tax benefits for fiscal 2024: Fiscal year ended January 31, 2024 Balance, January 31, 2023 $ — Increases for income tax positions related to prior years 844 Increases for income tax positions related to current years 396 Balance, January 31, 2024 $ 1,240

Net loss per share attributable

Net loss per share attributable to common stockholders	12 Months Ended
	Jan. 31, 2024
Earnings Per Share [Abstract]
Net loss per share attributable to common stockholders	Net loss per share attributable to common stockholders (a) Net loss per share attributable to common stockholders Basic and diluted net loss per share attributable to common stockholders was calculated as follows: Fiscal years ended January 31, 2024 2023 2022 Numerator: Net loss $ (136,885) $ (176,146) $ (118,161) Denominator: Weighted-average shares of common stock outstanding, basic and diluted 54,561,449 52,440,067 49,888,436 Net loss per share attributable to common stockholders $ (2.51) $ (3.36) $ (2.37) (b) Potential dilutive securities The Company’s potential dilutive securities, which include stock options, restricted stock units, performance stock awards, and grants under the Company's ESPP have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: Fiscal years ended January 31, 2024 2023 2022 Stock options to purchase common stock, restricted stock units and performance stock awards 7,273,621 6,745,591 5,632,823 Employee stock purchase plan 91,452 74,685 75,370 Total 7,365,073 6,820,276 5,708,193

Retirement savings plan

Retirement savings plan	12 Months Ended
	Jan. 31, 2024
Retirement Benefits [Abstract]
Retirement savings plan	Retirement savings planOn February 20, 2008, the Company established a retirement savings plan under Section 401(k) of the Internal Revenue Code (the “Plan”). The Plan covers substantially all U.S. full-time employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax and post-tax basis. Company contributions to the Plan may be made at the discretion of the Board of Directors of the Company. The Company did not make any contributions in the years ended January 31, 2024, 2023 or 2022

Related party transactions

Related party transactions	12 Months Ended
	Jan. 31, 2024
Related Party Transactions [Abstract]
Related party transactions	Related party transactions For the years ended January 31, 2024 and 2023, the Company recognized revenue totaling $1,174 and $775, respectively, for advertisements placed by a pharmaceutical company. One of the Company's independent members of its board of directors serves on the board of directors for this pharmaceutical company. As of January 31, 2024 and 2023, accounts receivable from the pharmaceutical company totaled $416 and $339, respectively. For the years ended January 31, 2024 and 2023, the Company recognized general and administrative expenses totaling $118 and $374, respectively, for software agreements with a software company. One of the Company's independent members of its board of directors served as the chief executive officer and on the board of directors for this software company until May 2023. This Company is no longer considered a related party subsequent to May 2023. As of January 31, 2023, prepaid expenses and other current assets included approximately $51 of payments to this software company. One of the Company's independent members of its board of directors has served as the chief financial officer of a software company since April 2022. The Company recognized de minimis expenses during the year ended January 31, 2024 for software agreements with this software company.

Acquisitions

Acquisitions	12 Months Ended
	Jan. 31, 2024
Business Combination and Asset Acquisition [Abstract]
Acquisitions	Acquisitions (a) Fiscal 2024 Acquisitions On June 30, 2023, the Company entered into the MediFind Acquisition to acquire 100% of the outstanding equity of MediFind for aggregate consideration payable of $8,871. A portion of the consideration was paid in cash at closing (subject to a customary working capital adjustment) with the remainder of the consideration settled through the issuance of 150,786 shares of the Company's common stock to certain MediFind stockholders. MediFind is a consumer-facing healthcare product that helps patients - especially those with serious, chronic and rare diseases - find better care faster. The MediFind Acquisition was accounted for as a business combination. The Company acquired MediFind to reinforce its commitment to patient-centered care and expand its offerings to consumers. On August 11, 2023, the Company entered into the Access Acquisition to acquire 100% of the outstanding equity of Access eForms for aggregate consideration payable of $37,411. A portion of the consideration was paid in cash at closing (subject to a customary working capital adjustment) with the remainder of the consideration settled through the issuance of 1,096,436 shares of the Company's common stock to the holders of the outstanding equity of Access eForms. Access is an innovative electronic forms management and automation provider that helps hospitals across the country streamline workflows, improve compliance and deliver a better patient experience. The Access Acquisition was accounted for as a business combination. The Company acquired Access to enhance and build on its existing functionality in the acute care space and to expand its network of clients and partners. On October 3, 2023, the Company entered into the ConnectOnCall Acquisition to acquire 100% of the outstanding equity of ConnectOnCall for aggregate consideration payable of $13,946. A portion of the consideration was paid in cash at closing with the remainder of the consideration payable in seven quarterly installments beginning in fiscal year 2024. The first installment was paid in January 2024. ConnectOnCall is a founder-owned company with an automated medical answering solution that routes and triages after-hours calls and manages high daytime call volumes. The ConnectOnCall solution is built on real-time Electronic Health Record (EHR) integrations, enhancing the control and transparency of patient information for providers or practices when returning calls. The Company acquired ConnectOnCall to expand its offerings to provider organizations, helping them make the call-triaging process more efficient and less expensive. The following table summarizes the estimated acquisition-date fair value of consideration transferred for each acquisition: MediFind Access ConnectOnCall Total Cash consideration paid to sellers $ 4,195 $ 6,766 $ 3,946 $ 14,907 Equity consideration paid to sellers 4,676 30,645 — 35,321 Liabilities incurred to sellers — — 10,000 10,000 Total fair value of acquisition consideration $ 8,871 $ 37,411 $ 13,946 $ 60,228 The acquisition-date fair value of equity consideration transferred was estimated using the closing stock price on the acquisition date for each acquisition. The acquisition-date fair value of liabilities incurred to sellers was estimated based on the timing of payments and an appropriate credit-adjusted discount rate of 9.3% per annum, determined with the assistance of a third-party appraiser. The Company accrues interest on the liability at 9.3% per annum. The Company recorded $294 of interest expense on the liability incurred to sellers during the year ended January 31, 2024. The total undiscounted liability incurred to the sellers of ConnectOnCall was $10,937. The following table summarizes the calculation of cash paid for each acquisition, net of cash acquired per the Company's consolidated statement of cash flows for the fiscal year ended January 31, 2024. MediFind Access ConnectOnCall Total Cash consideration paid to sellers $ 4,195 $ 6,766 $ 3,946 $ 14,907 Less: cash acquired (231) (80) (23) (334) Cash paid for acquisitions, net of cash acquired per statement of cash flows $ 3,964 $ 6,686 $ 3,923 $ 14,573 The purchase price was allocated to the tangible assets acquired, the identifiable intangible assets acquired and the liabilities assumed based on their acquisition-date estimated fair values or other measurement bases specified by ASC 805 - Business Combinations. The following table summarizes the allocation of the purchase price to the assets acquired and liabilities assumed at the date of each acquisition: MediFind Access ConnectOnCall Total Cash $ 231 $ 80 $ 23 $ 334 Accounts receivable 149 1,870 244 2,263 Other current assets 722 110 33 865 Identified intangible assets acquired 2,300 18,300 2,000 22,600 Goodwill 6,821 23,426 11,862 42,109 Total assets acquired $ 10,223 $ 43,786 $ 14,162 $ 68,171 Accounts payable (121) (196) (89) (406) Accrued liabilities (816) (884) (49) (1,749) Deferred revenue (292) (5,295) (78) (5,665) Deferred income tax liabilities (123) — — (123) Total purchase price $ 8,871 $ 37,411 $ 13,946 $ 60,228 The components of intangible assets acquired in the MediFind Acquisition were as follows: Estimated Useful Life Fair Value Technology 7 $ 1,200 Trademark 15 700 Customer relationships 10 400 Total identifiable intangible assets acquired $ 2,300 The weighted average amortization period for acquired intangible assets as of the date of acquisition is 10 years. The components of intangible assets acquired in the Access Acquisition were as follows: Estimated Useful Life Fair Value Technology 7 $ 5,200 Trademark 15 2,400 Customer relationships 15 10,700 Total identifiable intangible assets acquired $ 18,300 The weighted average amortization period for acquired intangible assets as of the date of acquisition is 13 years. The components of intangible assets acquired in the ConnectOnCall Acquisition were as follows: Estimated Useful Life Fair Value Technology 5 $ 1,500 Customer relationships 15 500 Total identifiable intangible assets acquired $ 2,000 The weighted average amortization period for acquired intangible assets as of the date of acquisition is 8 years. The Company, with the assistance of a third-party appraiser, assessed the fair value of the assets of MediFind, Access and ConnectOnCall. The fair value of the acquired technology and trademark assets were estimated using the relief from royalty method. The fair value of customer relationships was estimated using a multi-period excess earnings method. To calculate fair value, the Company used cash flows discounted at a rate considered appropriate given the inherent risks associated with each asset. The useful lives of the intangible assets were estimated based on the expected future economic benefit of the assets and are being amortized over the estimated useful life in proportion to the economic benefits consumed using the straight-line method. The amortization of intangible assets is not expected to be deductible for income tax purposes. The goodwill recognized in each of the acquisitions is primarily attributable to expected synergies of the combined businesses driven by integrating the license and technology into the solutions and engaging with patients and providers, as well as the acquisition of an assembled workforce. The goodwill recognized for the Access and ConnectOnCall acquisitions is expected to be tax deductible. The goodwill recognized for the MediFind acquisition is not expected to be tax deductible. During the year ended January 31, 2024, the Company incurred $3,106 of acquisition related costs for the MediFind, Access and ConnectOnCall acquisitions. These costs are primarily included within general and administrative expenses in the consolidated statements of operations. (b) Fiscal 2022 Insignia Acquisition On December 3, 2021, the Company entered into an agreement to acquire 100% of the outstanding equity of Insignia, a founder-led and mission-oriented company for cash consideration of $37,208. Insignia provides coaching and education solutions in conjunction with Insignia's exclusive worldwide license to the PAM. The PAM is a survey measuring a patient's knowledge, skills and ability to manage their care. The Company acquired Insignia to enable the Company to understand and engage patients in more personalized ways based on their level of activation. The Insignia Acquisition was accounted for as a business combination. Cash consideration paid to sellers $ 37,112 Liabilities incurred to sellers 96 Total fair value of acquisition consideration $ 37,208 The following table summarizes the calculation of cash paid for the acquisition of Insignia, net of cash acquired per the Company's consolidated statement of cash flows for the year ended January 31, 2022. Cash consideration paid to sellers $ 37,112 Less: cash acquired (2,689) Cash paid for acquisition of Insignia, net of cash acquired per statement of cash flows $ 34,423 During the fiscal year ended January 31, 2022, the Company incurred $720 of acquisition related costs for the Insignia Acquisition. These costs are primarily included within general and administrative expenses in our consolidated statement of operations. During the years ended January 31, 2023 and 2022, the Company recorded certain measurement period adjustments related to the acquisitions of Insignia and QueueDr. The financial impact of measurement period adjustments was not material.

Other events

Other events	12 Months Ended
	Jan. 31, 2024
Other Events [Abstract]
Other events	Other events In January 2024, the Company established a subsidiary in India, Phreesia India Private Limited (“Phreesia India”). During fiscal 2025, Phreesia India is expected to commence operations and support the Company’s business through various functions, including, but not limited to, customer operations, research and development, product management and support, sales and marketing, and finance and accounting, replacing support services that are currently outsourced to a third-party service provider in India.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2022
Pay vs Performance Disclosure
Net loss	$ (136,885)	$ (176,146)	$ (118,161)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended	12 Months Ended
	Jan. 31, 2024 shares	Jan. 31, 2024 shares
Trading Arrangements, by Individual
Non-Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Terminated	false
Michael Weintraub [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		On December 11, 2023, Michael Weintraub, a director of the Company, adopted a trading arrangement for the sale of securities of the Company’s common stock (a “Rule 10b5-1 Trading Plan”) that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Mr. Weintraub’s Rule 10b5-1 Trading Plan, which expires on October 1, 2024, provides for the sale of up to 24,848 shares of common stock.
Name	Michael Weintraub
Title	director
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	December 11, 2023
Arrangement Duration	295 days
Aggregate Available	24,848	24,848
Allison Hoffman [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		On December 20, 2023, Allison Hoffman, the General Counsel and Secretary of the Company, adopted a Rule 10b5-1 Trading Plan that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Ms. Hoffman’s Rule 10b5-1 Trading Plan, which expires on January 31, 2025, provides for the sale of up to 2,000 shares of common stock plus an additional number of shares that she could receive upon the future vesting of certain equity awards to be granted in connection with her fiscal year 2024 bonus and first half fiscal year 2025 bonus, net of any shares sold by Ms. Hoffman to satisfy applicable taxes, pursuant to the terms of her Rule 10b5-1 Trading Plan. The number of shares to be granted pursuant to Ms. Hoffman’s fiscal year 2024 bonus and first half fiscal 2025 bonus, and the number of shares to be sold by Ms. Hoffman to cover taxes, and thus the exact number of shares to be sold pursuant to Ms. Hoffman Rule 10b5-1 Trading Plan, can only be determined upon the occurrence of the future vesting events.
Name	Allison Hoffman
Title	General Counsel and Secretary
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	December 20, 2023
Arrangement Duration	408 days
Aggregate Available	2,000	2,000
Evan Roberts [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		On December 21, 2023, Evan Roberts, the Chief Operating Officer of the Company, adopted a Rule 10b5-1 Trading Plan that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Mr. Roberts’ Rule 10b5-1 Trading Plan, which expires on March 30, 2025, provides for the sale of up to 84,712 shares of common stock plus an additional number of shares that he could receive upon the future vesting of certain equity awards to be granted in connection with his fiscal year 2024 bonus and first half fiscal year 2025 bonus, net of any shares sold by Mr. Roberts to satisfy applicable taxes, pursuant to the terms of her Rule 10b5-1 Trading Plan. The number of shares to be granted pursuant to Mr. Roberts fiscal year 2024 bonus and first half fiscal 2025 bonus, and the number of shares to be sold by Mr. Roberts to cover taxes, and thus the exact number of shares to be sold pursuant to Mr. Roberts’ Rule 10b5-1 Trading Plan, can only be determined upon the occurrence of the future vesting events.
Name	Evan Roberts
Title	Chief Operating Officer
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	December 21, 2023
Arrangement Duration	465 days
Aggregate Available	84,712	84,712
Mark Smith [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		On December 22, 2023, Mark Smith, a director of the Company, adopted a Rule 10b5-1 Trading Plan that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Dr. Smith’s Rule 10b5-1 Trading Plan, which expires on October 1, 2024, provides for the sale of up to 13,000 shares of common stock.
Name	Mark Smith
Title	director
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	December 22, 2023
Arrangement Duration	284 days
Aggregate Available	13,000	13,000
Michael Davidoff [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		In connection with his departure from the Company, on December 15, 2023, Michael Davidoff, the Company’s former Senior Vice President of Payer Solutions, terminated a Rule 10b5-1 Trading Plan he had previously adopted with respect to the sale of the Company’s common stock. Mr. Davidoff’s Rule 10b5-1 Trading Plan was intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c). It was adopted on December 29, 2022, with an end date of July 31, 2024 and provided for the sale of up to 48,902 shares of common stock plus an additional number of shares that he could have received upon the future vesting of certain equity awards to be granted in connection with his fiscal year 2024 bonus, net of any shares sold by Mr. Davidoff to satisfy applicable taxes, pursuant to the terms of her Rule 10b5-1 Trading Plan. As of the date of termination of his Rule 10b5-1 Trading Plan, Mr. Davidoff had sold 47,902 shares of common stock under its terms.
Name	Michael Davidoff
Title	Senior Vice President
Adoption Date	December 29, 2022
Rule 10b5-1 Arrangement Terminated	true
Termination Date	December 15, 2023
Aggregate Available	48,902	48,902

Summary of significant accoun_2

Summary of significant accounting policies (Policies)	12 Months Ended
	Jan. 31, 2024
Accounting Policies [Abstract]
Consolidated financial statements	Consolidated financial statements The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("GAAP") and regulations of the Securities and Exchange Commission ("SEC") regarding annual financial reporting and include the accounts of Phreesia, Inc; its branch operation in Canada and its consolidated subsidiaries (or collectively, the "Company").
Fiscal year	Fiscal year The Company’s fiscal year ends on January 31. References to fiscal 2024, 2023 and 2022 refer to the fiscal years ending on January 31, 2024, 2023 and 2022, respectively.
Use of estimates	Use of estimates The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The most significant assumptions and estimates relate to the allowance for doubtful accounts, capitalized internal-use software, the determination of the useful lives of property and equipment, the fair value of securities underlying stock-based compensation, the fair value of identifiable assets and liabilities and deferred consideration in business acquisitions.
Revenue recognition	Revenue recognition The Company evaluates its contractual arrangements to determine the performance obligations and transaction prices. Revenue is allocated to each performance obligation and recognized when the related performance obligations are satisfied. See Note 5 for additional information regarding ASC 606, Revenue from Contracts with Customers , as well as for additional details about the Company's products and service lines.
Concentrations of credit risk and Risks and uncertainties	Concentrations of credit risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, accounts receivable and settlement assets. The Company’s cash and cash equivalents are held by established financial institutions. The Company does not require collateral from its customers and generally requires payment within 30 to 60 days of billing. Settlement assets are amounts due from well-established payment processing companies and normally take one two The Company is subject to a variety of risk factors, including the economy, data privacy and security laws and government regulations. Additionally, the Company is subject to other risks associated with the markets in which it operates including reliance on third-party vendors, partners, and service providers. The Company supplements its workforce with contractors and consultants, including a substantial number of contractors and consultants in international locations. Certain of the Company's service providers, including certain third-party software developers, are located in international locations subject to warfare and/or political and economic instability, such as Ukraine and India. As with any business, operation of the Company involves risk, including the risk of service interruption impacting the operations of the Company's business and the Company's customer’s facilities below expected levels of operation, shut downs due to the breakdown or failure of information technology and communications systems, changes in laws or regulations, political and economic instability, or catastrophic events such as fires, earthquakes, floods, explosions, global health concerns such as pandemics or other similar occurrences affecting the delivery of our productions and services. The occurrence of any of these events could significantly reduce or eliminate revenues generated, or significantly increase the expenses of the Company's operations, adversely impacting the Company’s operating results and the Company's ability to meet the Company's obligations and commitments. See Note 6 - Finance leases and other debt and Note 11 - Commitments and contingencies, for a summary of our contractual commitments as of January 31, 2024.
Cost of revenue (excluding depreciation and amortization)	Cost of revenue (excluding depreciation and amortization) Cost of revenue (excluding depreciation and amortization) primarily consists of personnel expenses for implementation and technical support, infrastructure costs for operation of our solutions such as hosting fees, and certain fees paid to various third-party providers for the use of their technology, as well as costs to verify insurance eligibility and benefits. Personnel expenses consist of salaries, stock-based compensation and benefits.
Payment processing expense	Payment processing expense Payment processing expense consists primarily of interchange fees set by payment card networks that are ultimately paid to the card-issuing financial institution, and assessment fees paid to payment card networks, and fees paid to third-party payment processors and gateways.
Sales and marketing	Sales and marketing Sales and marketing expense consists primarily of personnel costs, including salaries, stock-based compensation, benefits, bonuses and commission costs for our sales and marketing personnel. Sales and marketing expense also includes costs for advertising, promotional and other marketing activities, as well as certain fees paid to various
Research and development	Research and development Research and development expense consists of costs for the design, development, testing and enhancement of the Company’s products and services that do not meet the criteria for capitalization as internal-use software. These costs consist primarily of personnel costs, including salaries, stock-based compensation and benefits for our development personnel. Research and development expense also includes third-party partner fees and third-party consulting fees.
General and administrative	General and administrative General and administrative expense consists primarily of personnel costs, including salaries, stock-based compensation and benefits for our executive, finance, legal, human resources, information technology, and other administrative personnel. General and administrative expense also includes consulting, legal, security, accounting services and allocated overhead.
Depreciation and Amortization	Depreciation Depreciation represents depreciation expense for PhreesiaPads and Arrivals Kiosks (collectively, Phreesia hardware), data center and other computer hardware, purchased computer software, furniture and fixtures and leasehold improvements. Amortization primarily represents amortization of our capitalized internal-use software related to the Company's solutions as well as amortization of acquired intangible assets.
Cash and cash equivalents	Cash and cash equivalents The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents. The Company's money market accounts meet the definition of cash equivalents.
Settlement assets	Settlement assets Settlement assets represent amounts due from the Company’s payment processor for customer electronic processing transactions. Settlement assets are typically settled within one two
Settlement obligations	Settlement obligations Settlement obligations represent amounts due to customers for electronic processing transactions that have not been funded by the Company due to timing of settlement from the Company’s payment processor.
Accounts receivable	Accounts receivableAccounts receivable represent trade receivables, net of allowances for doubtful accounts. The Company estimates the allowance for doubtful accounts as its current estimate of expected credit loss over the life of the instrument. The Company determines the allowance based on historical trends of accounts receivable balances that have been written off and specific account analysis of at-risk customers, the length of time accounts are past due, a customer's current ability to pay its obligations to the Company, the condition of the industry as a whole, as well as expected future changes in credit losses. Accounts receivable are written off at the point that internal collections efforts have been exhausted.
Property and equipment	Property and equipment Property and equipment, including PhreesiaPads and Arrivals Kiosks, are stated at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the related assets. The estimated useful lives of the Company’s property and equipment have been estimated to be between three Upon sale or disposition of property and equipment, the cost and related accumulated depreciation are removed from their respective accounts and any gain or loss is reflected in the consolidated statements of operations.
Capitalized internal-use software	Capitalized internal-use software The Company capitalizes certain costs incurred for the development of computer software for internal use pursuant to ASC 350-40, Intangibles—Goodwill and Other—Internal use software . These costs relate to the development of its solutions. The Company capitalizes the costs during the development of the project, when it is determined that it is probable that the project will be completed, and the software will be used as intended. Costs related to preliminary project activities, post-implementation activities, training and maintenance are expensed as incurred. Internal-use software is amortized on a straight-line basis over its estimated useful life, which is generally three
Business combinations	Business combinations The Company uses its best estimates and assumptions to accurately assign fair value to the tangible and intangible assets acquired and liabilities assumed at the acquisition date. The Company’s estimates are inherently uncertain and subject to refinement. During the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the fair value of these tangible and intangible assets acquired and liabilities assumed, with the corresponding offset to goodwill. The Company continues to collect information and reevaluate these estimates and assumptions quarterly and records any adjustments to its estimates to goodwill provided that the Company is within the measurement period. Upon the conclusion of the measurement period or final determination of the fair value of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the consolidated statement of operations.
Goodwill and intangible assets	Goodwill and intangible assets Goodwill represents the excess of the consideration transferred over the fair value of the underlying net tangible and intangible assets acquired and liabilities assumed in connection with business combinations accounted for using the acquisition method of accounting. Goodwill is not amortized, but instead goodwill is required to be tested for impairment annually and under certain circumstances. We perform such testing of goodwill in the fourth quarter of each fiscal year, or as events occur or circumstances change that would more likely than not reduce the fair value below its carrying amount. The testing of goodwill is performed at the reporting unit level. The Company’s reporting unit is the same as its operating segment. The test begins with a qualitative assessment to determine whether it is “more likely than not” that the fair value of the reporting unit is less than its carrying amount. If it is concluded that it is “more likely than not” that the fair value of a reporting unit is less than its carrying amount, the Company performs a quantitative goodwill impairment test by calculating the fair value of the reporting unit and comparing that fair value to the carrying value of the reporting unit. If the estimated fair value of the reporting unit is less than its carrying amount, the Company records a goodwill impairment to reduce the carrying amount of goodwill by the amount by which the fair value of the reporting unit is less than its carrying amount. All other intangible assets associated with purchased intangibles, consisting of customer relationships, acquired technology, acquired trademarks and acquired licenses, are recorded at acquisition-date fair value less accumulated amortization and are amortized on a straight-line basis over their estimated remaining economic lives.
Long-lived assets	Long-lived assets Long-lived assets, such as property and equipment, intangible assets, capitalized internal-use software and operating lease right-of-use assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares the undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. There were no impairment charges recognized in the consolidated statements of operations during any of the periods presented.
Income taxes	(u) Income taxes An asset and liability approach is used for financial accounting and reporting of current and deferred income taxes. Deferred income tax assets and liabilities are computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future. Such deferred income tax asset and liability computations are based on enacted tax laws and rates applicable to periods in which the differences are expected to affect taxable income or loss. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company follows the guidance in ASC 740, Accounting for Uncertainty in Income Taxes . ASC 740 clarifies the accounting for uncertainty in income taxes recognized in a Company’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC 740 also provides guidance on de-recognition, classification, interest and penalties, accounting in the interim periods, and disclosure. The Company reviews and evaluates tax positions in its major jurisdictions and determines whether or not there are uncertain tax positions that require financial statement recognition and the recording of a tax liability or the reduction of a tax asset. The Company would recognize tax related interest and penalties, if applicable, as a component of its provision for income taxes.
Segment information	Segment information Operating segments are defined as components of an enterprise about which separate financial information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company defines the term “chief operating decision maker” to be its Chief Executive Officer. The Company’s Chief Executive Officer reviews the financial information presented on an entire company basis for purposes of allocating resources and evaluating our financial performance. Accordingly, we have determined that we operate in a single reportable operating segment. Additionally, substantially all of the Company's revenues and long-lived assets are located in the U.S. Since the Company operates in one operating segment and substantially all of the Company's revenues and long-lived assets are located in the U.S., all required financial segment information can be found in the accompanying consolidated financial statements.
Stock-based compensation	Stock-based compensation The Company has stock-based compensation plans under which various types of equity-based awards are granted, including stock options, restricted stock units ("RSUs"), performance-based RSUs, and market-based performance stock units ("PSUs"). The compensation for the stock-based awards is recognized in accordance with ASC 718 , Compensation — Stock Compensation , which requires that compensation cost be recognized for awards based on the grant-date fair value of the award. That cost is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the award. For performance-based RSUs, the number of shares expected to vest is estimated at each reporting date based on management's expectations regarding the relevant performance criteria. The Company adjusts stock compensation expense for forfeitures of stock-based compensation awards in the periods the forfeitures occur. The fair value of stock options is estimated at the time of grant using the Black-Scholes option pricing model, which requires the use of inputs and assumptions such as the exercise price of the option, expected term, risk-free interest rate, expected volatility and dividend yield, and the value of the Company's common stock (which is estimated for awards granted prior to our IPO). The Company does not estimate forfeitures in recognizing stock-based compensation expense. The fair value of the RSUs is equal to the fair value of the Company's common stock on the grant date of the award. The fair value of market-based PSUs is estimated at the time of grant using a Monte Carlo simulation which compares Phreesia's projected total shareholder return ("TSR") to the projected TSR of the Russell 3000 Index (the "Peer Group") and estimates the value of shares to be issued based on the vesting conditions of the PSUs. The Monte Carlo simulation requires the use of inputs and assumptions such as the grant-date closing stock price, simulation, expected volatility, correlation coefficient to the Russell 3000 Index, risk-free interest rate and dividend yield. During fiscal 2022, the Company adopted the Phreesia, Inc. 2019 Employee Stock Purchase Plan ("ESPP" or "the Plan"). The Company will record compensation expense based on the grant date fair value per award granted multiplied by the number of awards granted to the employee for the purchase period. The number of awards granted to the employee for the purchase period is equal to the expected employee contributions divided by 85% of the closing stock price on the offering date. For liability-classified performance based stock bonus awards, at the beginning of the year, the Company offers eligible employees the option to elect to receive their year-end performance bonus in stock. Bonuses settled in stock are accounted for as stock-based compensation awards vesting based on a performance condition and are classified as liabilities because they represent a liability settled in a variable number of shares.
Fair value of financial instruments	Fair value of financial instruments Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for the sale of an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are required to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market. Level 3—Unobservable inputs which are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
Equity offering costs	Equity offering costs The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs will be recorded in stockholders’ equity as a reduction of additional paid-in capital generated as a result of the offering, to the extent there are sufficient proceeds. Should the equity financing no longer be considered probable of being consummated, all deferred offering costs would be charged to operating expenses in the accompanying consolidated statement of operations.
Foreign currency	Foreign currency The Company has a branch office in Canada that provides operational support. The functional currency of the Company’s foreign branch is the U.S. dollar. Accordingly, assets and liabilities of the Company’s foreign branch are re-measured into U.S. dollars at the exchange rates in effect at the reporting date with differences recorded as transaction gains and losses within other income (expense), net.
New accounting pronouncements	New accounting pronouncements Impact of recently adopted accounting pronouncements During the year ended January 31, 2024, the Company did not adopt any accounting pronouncements that materially impacted the Company's financial statements. Recent accounting pronouncements not yet adopted In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) 2023-07, Segment Reporting. The new standard requires enhanced disclosures about significant segment expenses and other segment items and requires companies to disclose all annual disclosures about segments in interim periods. The new standard also permits companies to disclose more than one measure of segment profit or loss, requires disclosure of the title and position of the Chief Operating Decision Maker, and requires companies with a single reportable segment to provide all disclosures required by Topic 280 – Segment Reporting. The new standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. Companies are required to apply ASU 2023-07 retrospectively to all periods presented. The Company is currently evaluating the impact that ASU 2023-07 will have on its financial statements and related disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The provisions of ASU 2023-09 are effective for annual periods beginning after December 15, 2024; early adoption is permitted. The Company is currently evaluating the impact that ASU 2023-09 will have on its financial statements and related disclosures.

Composition of certain financ_2

Composition of certain financial statement captions (Tables)	12 Months Ended
	Jan. 31, 2024
Composition Of Certain Financial Statement [Abstract]
Schedule of accrued expenses	Accrued expenses at January 31, 2024 and 2023 are as follows: January 31, 2024 2023 Payroll-related expenses and taxes $ 8,981 $ 4,461 Stock-based compensation liability 5,890 5,884 Payment processing fees liability 6,008 4,796 Acquisition-related liabilities 1,888 96 Income and other tax liabilities 3,042 1,491 Information technology services 5,927 2,249 Other 5,394 2,833 Total $ 37,130 $ 21,810
Schedule of property and equipment	Property and equipment at January 31, 2024 and 2023 are as follows: Useful life January 31, 2024 2023 PhreesiaPads and Arrivals Kiosks 3 $ 18,610 $ 17,932 Computer equipment 3 62,888 54,485 Computer software 3 to 5 11,687 8,571 Hardware development 3 576 529 Total property and equipment $ 93,761 $ 81,517 Less: accumulated depreciation (76,859) (59,847) Property and equipment — net $ 16,902 $ 21,670
Schedule of intangible assets	The following presents the details of intangible assets as of January 31, 2024 and 2023. Useful Life January 31, (years) 2024 2023 Acquired technology 5 to 7 $ 9,310 $ 1,410 Customer relationship 7 to 15 17,940 6,340 License 15 6,200 6,200 Trademarks 15 3,100 — Total intangible assets, gross carrying value $ 36,550 $ 13,950 Less: accumulated amortization (4,925) (2,549) Net carrying value $ 31,625 $ 11,401
Schedule of estimated amortization expense for intangible assets	The estimated amortization expense for intangible assets for the next five years and thereafter is as follows as of January 31, 2024: January 31, 2024 2025 $ 3,481 2026 3,450 2027 3,157 2028 3,157 Thereafter 18,380 Total $ 31,625
Schedule of goodwill	The following table presents a roll-forward of goodwill for the years ended January 31, 2023 and 2024: Balance at January 31, 2022 $ 33,621 Measurement period adjustments to goodwill during the year ended January 31, 2023 115 Balance at January 31, 2023 $ 33,736 Goodwill acquired during the year ended January 31, 2024 42,109 Balance at January 31, 2024 $ 75,845
Schedule of accounts receivable	Accounts Receivable as of January 31, 2024 and 2023 are as follows: January 31, 2024 2023 Billed $ 62,880 $ 51,458 Unbilled 3,375 989 Total accounts receivable, gross $ 66,255 $ 52,447 Less: accounts receivable allowances (1,392) (1,053) Total accounts receivable $ 64,863 $ 51,394
Schedule of allowance for doubtful accounts	Activity in the Company's allowance for doubtful accounts was as follows for the years ended January 31, 2024 and 2023: Balance, January 31, 2022 $ 863 Bad debt expense 587 Write-offs and adjustments (397) Balance, January 31, 2023 $ 1,053 Bad debt expense 377 Increases due to acquisitions 681 Write-offs and adjustments (719) Balance, January 31, 2024 $ 1,392
Schedule of prepaid and other current assets	Prepaid and other current assets as of January 31, 2024 and 2023 are as follows: January 31, 2024 2023 Prepaid software and business systems $ 4,922 $ 3,426 Prepaid data center expenses 3,872 2,389 Prepaid insurance 1,257 1,552 Other prepaid expenses and other current assets 4,410 3,342 Total prepaid and other current assets $ 14,461 $ 10,709

Revenue and contract costs (Tab

Revenue and contract costs (Tables)	12 Months Ended
	Jan. 31, 2024
Revenue from Contract with Customer [Abstract]
Schedule of rollforward of contract assets and contract liabilities	The following table represents a roll-forward of contract assets: January 31, 2024 2023 Beginning Balance $ 989 $ 392 Amount transferred to receivables from beginning balance of contract assets (989) (392) Contract asset additions, net of reclassification to receivables 3,375 989 Ending Balance $ 3,375 $ 989 The following table represents a roll-forward of deferred revenue: January 31, 2024 2023 Beginning Balance $ 17,813 $ 16,558 Revenue recognized that was included in deferred revenue at the beginning of the period (17,388) (16,005) Deferred revenue added from acquisitions 5,665 — Other current year activity in deferred revenue 18,120 17,260 Ending Balance $ 24,210 $ 17,813
Schedule of deferred contract acquisition costs	The following table represents a roll-forward of deferred contract acquisition costs: January 31, 2024 2023 Beginning balance $ 2,810 $ 4,079 Additions to deferred contract acquisition costs — 427 Amortization of deferred contract acquisition costs (1,056) (1,696) Ending balance $ 1,754 $ 2,810 Deferred contract acquisition costs, current (to be amortized in next 12 months) $ 768 $ 1,056 Deferred contract acquisition costs, non-current 986 1,754 Total deferred contract acquisition costs $ 1,754 $ 2,810

Finance leases and other debt (

Finance leases and other debt (Tables)	12 Months Ended
	Jan. 31, 2024
Debt Disclosure [Abstract]
Schedule of long-term debt instruments	As of January 31, 2024 and 2023, the Company had the following outstanding finance lease liabilities and other debt: January 31, 2024 2023 Finance leases $ 8,309 $ 7,651 Financing arrangements 3,124 46 Accrued interest and payments 23 200 Total finance lease liabilities and other debt $ 11,456 $ 7,897 Less: current portion of finance lease liabilities and other debt (6,056) (5,172) Long-term finance lease liabilities and other debt $ 5,400 $ 2,725
Schedule of long-term debt and finance lease maturities	Maturities of finance leases and other debt in each of the next five years and thereafter are as follows: Total Finance Leases Other Debt Fiscal year ending January 31, 2025 $ 6,056 $ 4,958 $ 1,098 2026 4,167 2,837 1,330 2027 1,233 514 719 Total maturities of finance leases and other debt $ 11,456 $ 8,309 $ 3,147
Schedule of components of interest income (expense)	The following table presents the components of interest income (expense), net: Fiscal years ended January 31, 2024 2023 2022 Interest expense (1) $ (1,854) $ (1,411) $ (1,163) Interest income 4,065 2,475 79 Interest income (expense), net $ 2,211 $ 1,064 $ (1,084) (1) Includes amortization of deferred financing costs and original issue discount

Equity-based compensation (Tabl

Equity-based compensation (Tables)	12 Months Ended
	Jan. 31, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of stock based compensation by type of award	The following table sets forth stock-based compensation by type of award: For the fiscal years ended 2024 2023 2022 RSUs $ 53,474 $ 42,214 $ 24,222 Liability awards 9,047 7,641 7,055 PSUs 9,206 7,282 2,389 Stock options 45 1,489 2,294 ESPP 1,256 1,521 763 Total stock-based compensation $ 73,028 $ 60,147 $ 36,723
Schedule of stock based compensation in financial statements	The following table sets forth the presentation of stock-based compensation in the Company's consolidated financial statements: For the fiscal years ended 2024 2023 2022 Stock-based compensation expense recorded to additional paid-in capital (1) $ 63,981 $ 52,506 $ 29,668 Stock-based compensation expense recorded to accrued expenses 9,047 7,641 7,055 Total stock-based compensation 73,028 60,147 36,723 Less: stock-based compensation expense capitalized as internal-use software (1,415) (1,372) (489) Stock-based compensation expense per consolidated statements of operations (2) $ 71,613 $ 58,775 $ 36,234 (1) Stock-based compensation included in the Company's consolidated statements of stockholders' equity is consistent with these amounts. (2) Non-cash stock-based compensation expense included in the Company's consolidated statements of cash flows for the fiscal year ended January 31, 2022 was $36,144, and excluded $90 of cash-settled stock-based compensation expense included in the Company's statements of operations.
Schedule of restricted stock unit activity	Restricted stock units Unvested, January 31, 2021 2,053,038 Granted during year 1,836,534 Vested (559,767) Forfeited and expired (195,966) Unvested, January 31, 2022 3,133,839 Granted during year 2,907,838 Vested (1,626,679) Forfeited and expired (497,245) Unvested, January 31, 2023 3,917,753 Granted during year (1) 2,419,679 Vested (1,912,432) Forfeited and expired (624,790) Unvested, January 31, 2024 3,800,210 (1) Includes 24,125 awards granted pursuant to the 2023 Inducement Award Plan.
Schedule of stock option activity	Stock option activity for the fiscal years ended January 31, 2024, 2023 and 2022 is as follows: Number of Weighted- Weighted- Aggregate Intrinsic Outstanding — January 31, 2021 3,211,354 $ 4.67 Granted during the year — $ — Exercised (1,439,186) $ 2.88 Forfeited (67,018) $ 9.02 Outstanding and expected to vest — January 31, 2022 1,705,150 $ 6.01 5.94 $ 42,938 Outstanding — January 31, 2022 1,705,150 $ 6.01 Granted during the year — $ — Exercised (311,743) $ 4.92 Forfeited and expired (8,214) $ 4.68 Outstanding and expected to vest — January 31, 2023 1,385,193 $ 6.26 5.06 $ 43,341 Outstanding — January 31, 2023 1,385,193 $ 6.26 Granted during the year — $ — Exercised (249,247) $ 3.42 Forfeited and expired (12,508) $ 5.87 Outstanding and expected to vest — January 31, 2024 1,123,438 $ 6.89 4.54 $ 20,884 Exercisable — January 31, 2024 1,123,438 $ 6.89 4.54 $ 20,884 Amount vested during year ended January 31, 2024 24,565 $ 13.41
Schedule of measurement inputs and valuation techniques	The fair value of the PSUs granted during the fiscal years ended January 31, 2024, 2023 and 2022, respectively, was estimated using the following assumptions: Fiscal years ended January 31, 2024 2023 2022 Correlation coefficient 0.5238 0.4957 0.3878 Valuation date stock price $ 22.94 $ 35.41 $ 36.03 Simulation term 3.00 Years 3.00 Years 2.99 Years Volatility 64.58 % 64.98 % 44.32 % Risk-free rate 4.05 % 3.84 % 1.23 % Dividend yield — % — % — % Weighted average fair value of grants $ 36.42 $ 56.52 $ 48.47
Schedule of market-based performance stock unit activity	Performance Outstanding, February 1, 2021 70,806 Granted during the year ended January 31, 2022 325,410 Outstanding, February 1, 2022 396,216 Granted during the year ended January 31, 2023 255,572 Vested — Forfeited and expired (3,555) Outstanding, February 1, 2023 648,233 Granted during the year ended January 31, 2024 576,680 Vested (67,251) Forfeited (117,443) Outstanding, January 31, 2024 1,040,219
Schedule of ESPP valuation assumptions	The fair value of shares granted under the ESPP during the year ended January 31, 2024 was estimated using a Black-Scholes pricing model with the following assumptions: Year ended Year ended Year ended Risk-free interest rate 5.30 % 3.68 % 0.17 % Expected dividends none none none Expected term (in years) 0.49 years 0.47 years 0.49 years Volatility 62.4 % 74.8 % 55.7 %

Fair value measurements (Tables

Fair value measurements (Tables)	12 Months Ended
	Jan. 31, 2024
Fair Value Disclosures [Abstract]
Schedule of fair value, assets and liabilities measured on recurring basis	The following table presents information about the Company's assets and liabilities that are measured at fair value as of January 31, 2024 and indicates the classification of each item within the fair value hierarchy: Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Balance as of January 31, 2024 Money market mutual funds $ 58,942 $ — $ — $ 58,942 Total assets $ 58,942 $ — $ — $ 58,942 The following table presents information about the Company's assets and liabilities that are measured at fair value as of January 31, 2023 and indicates the classification of each item within the fair value hierarchy: Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Balance as of January 31, 2023 Money market mutual funds $ 163,563 $ — $ — $ 163,563 Total assets $ 163,563 $ — $ — $ 163,563

Leases (Tables)

Leases (Tables)	12 Months Ended
	Jan. 31, 2024
Leases [Abstract]
Schedule of operating and finance leases	Supplemental balance sheet information related to operating and finance leases as of January 31, 2024 and 2023 was as follows: January 31, 2024 2023 Operating leases: Lease right-of-use assets $ 266 $ 569 Lease liabilities, current $ 393 $ 934 Lease liabilities, non-current 134 349 Total operating lease liabilities $ 527 $ 1,283 Finance leases: Property and equipment, at cost $ 35,250 $ 27,813 Accumulated depreciation (27,399) (20,657) Property and equipment, net $ 7,851 $ 7,156 Lease liabilities, current (included in Current portion of finance lease liabilities and other debt) 4,958 4,926 Lease liabilities, non-current (included in Long-term finance lease liabilities and other debt) 3,351 2,725 Total finance lease liabilities $ 8,309 $ 7,651
Schedule of lease expense and cash flow information	The components of lease expense for the years ended January 31, 2024, 2023 and 2022 were as follows: Fiscal years ended 2024 2023 2022 Operating leases: Operating lease cost $ 740 $ 1,835 $ 1,096 Variable lease cost 47 62 223 Total operating lease cost $ 787 $ 1,897 $ 1,319 Finance leases: Amortization of right-of-use assets $ 6,742 $ 5,632 $ 4,636 Interest on lease liabilities 580 368 378 Total finance lease cost $ 7,322 $ 6,000 $ 5,014 Other supplemental cash flow information for the years ended January 31, 2024, 2023 and 2022 was as follows: Fiscal years ended 2024 2023 2022 Supplemental cash flow information Cash paid for amounts included in the measurement of lease liabilities: Operating cash used for operating leases $ 1,238 $ 1,347 $ 1,206 Operating cash used for finance leases 535 396 377 Financing cash used for finance leases 6,779 5,731 4,267
Schedule of maturing lease commitments of operating leases	The following represents a schedule of maturing lease commitments for operating and finance leases as of January 31, 2024: January 31, 2024 Operating Finance Maturity of lease liabilities Fiscal year ending January 31, 2025 $ 404 $ 5,343 2026 86 2,986 2027 42 521 2028 7 — Total future minimum lease payments $ 539 $ 8,850 Less: interest (12) (541) Present value of lease liabilities $ 527 $ 8,309
Schedule of maturing lease commitments of finance leases	The following represents a schedule of maturing lease commitments for operating and finance leases as of January 31, 2024: January 31, 2024 Operating Finance Maturity of lease liabilities Fiscal year ending January 31, 2025 $ 404 $ 5,343 2026 86 2,986 2027 42 521 2028 7 — Total future minimum lease payments $ 539 $ 8,850 Less: interest (12) (541) Present value of lease liabilities $ 527 $ 8,309

Commitments and contingencies (

Commitments and contingencies (Tables)	12 Months Ended
	Jan. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Schedule of Minimum Payments Under Purchase Commitments	Other contractual commitments consist primarily of non-cancelable purchase commitments to support our technology infrastructure as well as installment payments for deferred consideration payable in connection with the acquisition of ConnectOnCall. Future minimum payments under our non-cancelable contractual commitments as of January 31, 2024 are presented in the table below. Purchase obligations Fiscal year ending January 31, 2025 $ 15,067 2026 9,171 2027 4,520 2028 2,260 Total $ 31,018

Income taxes (Tables)

Income taxes (Tables)	12 Months Ended
	Jan. 31, 2024
Income Tax Disclosure [Abstract]
Schedule of income tax (benefit)	The Company's income tax provision consisted of the following for fiscal 2024, 2023 and 2022: Fiscal years ended January 31, 2024 2023 2022 Current tax Federal $ — $ — $ — State 76 49 39 Foreign 1,239 — — Deferred tax Federal 38 109 — State — — — Foreign 190 325 143 Total provision for income taxes $ 1,543 $ 483 $ 182
Schedule of effective tax rate	A reconciliation of the statutory U.S. federal income tax rate to the Company's effective tax rate for fiscal 2024, 2023 and 2022 is as follows: Fiscal years ended January 31, 2024 2023 2022 Federal income tax benefit at statutory rate 21 % 21 % 21 % State and local tax, net of federal benefit 3 % 5 % 9 % Permanent differences — % — % — % Equity compensation — % — % 6 % Foreign taxes (1) % — % — % Other — % — % — % Change in valuation allowance (24) % (26) % (36) % Effective income tax rate (1) % — % — %
Schedule of deferred tax assets and liabilities	The significant components of the Company's deferred income tax assets and liabilities as of January 31, 2024 and 2023 are as follows: January 31, Deferred tax (liabilities) assets 2024 2023 Net operating loss carryforwards $ 160,791 $ 131,574 Stock based compensation 9,278 7,765 Accruals, reserves, and other expenses 3,668 2,763 Reserve for bad debts 793 530 Disallowed interest expense 1,041 1,934 Depreciation and amortization 1,829 — Total deferred tax assets 177,400 144,566 Less: valuation allowance (176,641) (143,135) Net deferred tax (liabilities) assets 759 1,431 Depreciation and amortization — (295) Intangible assets (569) (305) Deferred contract acquisition costs (460) (750) Total deferred tax liabilities (1,029) (1,350) Net deferred tax (liabilities) assets $ (270) $ 81
Schedule of unrecognized tax benefits	The following is a roll-forward of the Company's total gross unrecognized tax benefits for fiscal 2024: Fiscal year ended January 31, 2024 Balance, January 31, 2023 $ — Increases for income tax positions related to prior years 844 Increases for income tax positions related to current years 396 Balance, January 31, 2024 $ 1,240

Net loss per share attributab_2

Net loss per share attributable to common stockholders (Tables)	12 Months Ended
	Jan. 31, 2024
Earnings Per Share [Abstract]
Schedule of earnings per share, basic and diluted	Basic and diluted net loss per share attributable to common stockholders was calculated as follows: Fiscal years ended January 31, 2024 2023 2022 Numerator: Net loss $ (136,885) $ (176,146) $ (118,161) Denominator: Weighted-average shares of common stock outstanding, basic and diluted 54,561,449 52,440,067 49,888,436 Net loss per share attributable to common stockholders $ (2.51) $ (3.36) $ (2.37)
Schedule of shares excluded from computation of diluted net loss per share	The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: Fiscal years ended January 31, 2024 2023 2022 Stock options to purchase common stock, restricted stock units and performance stock awards 7,273,621 6,745,591 5,632,823 Employee stock purchase plan 91,452 74,685 75,370 Total 7,365,073 6,820,276 5,708,193

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Jan. 31, 2024
Business Combination and Asset Acquisition [Abstract]
Schedule of purchase price considerations at acquisition date	The following table summarizes the estimated acquisition-date fair value of consideration transferred for each acquisition: MediFind Access ConnectOnCall Total Cash consideration paid to sellers $ 4,195 $ 6,766 $ 3,946 $ 14,907 Equity consideration paid to sellers 4,676 30,645 — 35,321 Liabilities incurred to sellers — — 10,000 10,000 Total fair value of acquisition consideration $ 8,871 $ 37,411 $ 13,946 $ 60,228 The following table summarizes the calculation of cash paid for each acquisition, net of cash acquired per the Company's consolidated statement of cash flows for the fiscal year ended January 31, 2024. MediFind Access ConnectOnCall Total Cash consideration paid to sellers $ 4,195 $ 6,766 $ 3,946 $ 14,907 Less: cash acquired (231) (80) (23) (334) Cash paid for acquisitions, net of cash acquired per statement of cash flows $ 3,964 $ 6,686 $ 3,923 $ 14,573 Cash consideration paid to sellers $ 37,112 Liabilities incurred to sellers 96 Total fair value of acquisition consideration $ 37,208 The following table summarizes the calculation of cash paid for the acquisition of Insignia, net of cash acquired per the Company's consolidated statement of cash flows for the year ended January 31, 2022. Cash consideration paid to sellers $ 37,112 Less: cash acquired (2,689) Cash paid for acquisition of Insignia, net of cash acquired per statement of cash flows $ 34,423
Schedule of allocation of purchase price of assets acquired and liabilities assumed	The following table summarizes the allocation of the purchase price to the assets acquired and liabilities assumed at the date of each acquisition: MediFind Access ConnectOnCall Total Cash $ 231 $ 80 $ 23 $ 334 Accounts receivable 149 1,870 244 2,263 Other current assets 722 110 33 865 Identified intangible assets acquired 2,300 18,300 2,000 22,600 Goodwill 6,821 23,426 11,862 42,109 Total assets acquired $ 10,223 $ 43,786 $ 14,162 $ 68,171 Accounts payable (121) (196) (89) (406) Accrued liabilities (816) (884) (49) (1,749) Deferred revenue (292) (5,295) (78) (5,665) Deferred income tax liabilities (123) — — (123) Total purchase price $ 8,871 $ 37,411 $ 13,946 $ 60,228
Schedule of intangible assets acquired	The components of intangible assets acquired in the MediFind Acquisition were as follows: Estimated Useful Life Fair Value Technology 7 $ 1,200 Trademark 15 700 Customer relationships 10 400 Total identifiable intangible assets acquired $ 2,300 The components of intangible assets acquired in the Access Acquisition were as follows: Estimated Useful Life Fair Value Technology 7 $ 5,200 Trademark 15 2,400 Customer relationships 15 10,700 Total identifiable intangible assets acquired $ 18,300 The components of intangible assets acquired in the ConnectOnCall Acquisition were as follows: Estimated Useful Life Fair Value Technology 5 $ 1,500 Customer relationships 15 500 Total identifiable intangible assets acquired $ 2,000

Background and liquidity (Detai

Background and liquidity (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2024	Dec. 04, 2023
Senior Secured Asset-based Revolving Credit Facility | Revolving Credit Facility | Line of Credit
Debt Instrument [Line Items]
Line of credit borrowing capacity		$ 50,000
Third SVB Facility
Debt Instrument [Line Items]
Number of months with sufficient funds to operate (in months)	12 months

Summary of significant accoun_3

Summary of significant accounting policies (Details)	12 Months Ended
	Jan. 31, 2024 USD ($) segment processor	Jan. 31, 2023 USD ($)	Jan. 31, 2022 USD ($)
Accounting Policies [Line Items]
Settlement period (in days)	2 days
Number of third party payment processors | processor	1
Advertising expense	$ 1,900,000	$ 2,634,000	$ 4,007,000
Allowance for doubtful accounts	1,392,000	1,053,000	863,000
Asset impairment charges	$ 0	$ 0	$ 0
Number of operating segment | segment	1
ESPP
Accounting Policies [Line Items]
Employee purchase price of common stock (as a percent)	85%
Minimum
Accounting Policies [Line Items]
Customer payment period	30 days
Settlement period (in days)	1 day
Useful life (in years)	3 years
Minimum | Computer software
Accounting Policies [Line Items]
Finite-lived intangible asset, useful life	3 years
Maximum
Accounting Policies [Line Items]
Customer payment period	60 days
Settlement period (in days)	2 days
Useful life (in years)	7 years
Maximum | Computer software
Accounting Policies [Line Items]
Finite-lived intangible asset, useful life	5 years

Composition of certain financ_3

Composition of certain financial statement captions - Schedule of accrued expenses (Details) - USD ($) $ in Thousands	Jan. 31, 2024	Jan. 31, 2023
Composition Of Certain Financial Statement [Abstract]
Payroll-related expenses and taxes	$ 8,981	$ 4,461
Stock-based compensation liability	5,890	5,884
Payment processing fees liability	6,008	4,796
Acquisition-related liabilities	1,888	96
Income and other tax liabilities	3,042	1,491
Information technology services	5,927	2,249
Other	5,394	2,833
Total	$ 37,130	$ 21,810

Composition of certain financ_4

Composition of certain financial statement captions - Narrative (Details) - USD ($)	12 Months Ended
	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Other current liabilities	$ 5,875,000	$ 0
Other long-term liabilities	2,857,000	0
Depreciation	17,584,000	17,988,000	$ 14,985,000
Property and equipment, at cost	35,250,000	27,813,000
Assets under finance lease, accumulated amortization	27,399,000	20,657,000
Capitalized cost of computer software	19,521,000	23,604,000	12,830,000
Capitalized computed software amortization	9,527,000	5,945,000	5,664,000
Amortization of intangible assets	2,376,000	1,371,000	653,000
Impairment of goodwill	0	0	$ 0
Capitalized implementation costs	1,532,000	1,532,000
Capitalized implementation costs, accumulated amortization	$ 1,021,000,000	$ 610,000,000
Acquired technology
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, remaining amortization period (in years)	6 years	2 years 8 months 12 days
Customer relationship
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, remaining amortization period (in years)	12 years 4 months 24 days	8 years 3 months 18 days
License
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, remaining amortization period (in years)	12 years 9 months 18 days	13 years 9 months 18 days
Trademarks
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, remaining amortization period (in years)	14 years 6 months
Computer equipment
Finite-Lived Intangible Assets [Line Items]
Property and equipment, at cost	$ 35,250,000	$ 27,813,000
Assets under finance lease, accumulated amortization	$ 27,399,000	$ 20,657,000

Composition of certain financ_5

Composition of certain financial statement captions - Schedule of property and equipment (Details) - USD ($) $ in Thousands	Jan. 31, 2024	Jan. 31, 2023
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 93,761	$ 81,517
Less: accumulated depreciation	(76,859)	(59,847)
Property and equipment — net	$ 16,902	21,670
Minimum
Property, Plant and Equipment [Line Items]
Useful life (in years)	3 years
Maximum
Property, Plant and Equipment [Line Items]
Useful life (in years)	7 years
PhreesiaPads and Arrivals Kiosks
Property, Plant and Equipment [Line Items]
Useful life (in years)	3 years
Total property and equipment	$ 18,610	17,932
Computer equipment
Property, Plant and Equipment [Line Items]
Useful life (in years)	3 years
Total property and equipment	$ 62,888	54,485
Computer software
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 11,687	8,571
Computer software | Minimum
Property, Plant and Equipment [Line Items]
Useful life (in years)	3 years
Computer software | Maximum
Property, Plant and Equipment [Line Items]
Useful life (in years)	5 years
Hardware development
Property, Plant and Equipment [Line Items]
Useful life (in years)	3 years
Total property and equipment	$ 576	$ 529

Composition of certain financ_6

Composition of certain financial statement captions - Schedule of intangible assets (Details) - USD ($) $ in Thousands	Jan. 31, 2024	Jan. 31, 2023
Finite-Lived Intangible Assets [Line Items]
Total intangible assets, gross carrying value	$ 36,550	$ 13,950
Less: accumulated amortization	(4,925)	(2,549)
Net carrying value	31,625	11,401
Acquired technology
Finite-Lived Intangible Assets [Line Items]
Total intangible assets, gross carrying value	$ 9,310	1,410
Acquired technology | Minimum
Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	5 years
Acquired technology | Maximum
Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	7 years
Customer relationship
Finite-Lived Intangible Assets [Line Items]
Total intangible assets, gross carrying value	$ 17,940	6,340
Customer relationship | Minimum
Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	7 years
Customer relationship | Maximum
Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	15 years
License
Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	15 years
Total intangible assets, gross carrying value	$ 6,200	6,200
Trademarks
Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	15 years
Total intangible assets, gross carrying value	$ 3,100	$ 0

Composition of certain financ_7

Composition of certain financial statement captions - Schedule of future amortization expense (Details) - USD ($) $ in Thousands	Jan. 31, 2024	Jan. 31, 2023
Composition Of Certain Financial Statement [Abstract]
2025	$ 3,481
2026	3,450
2027	3,157
2028	3,157
Thereafter	18,380
Net carrying value	$ 31,625	$ 11,401

Composition of certain financ_8

Composition of certain financial statement captions - Schedule of goodwill roll-forward (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2024	Jan. 31, 2023
Goodwill [Roll Forward]
Goodwill balance at beginning of period	$ 33,736	$ 33,621
Measurement period adjustments to goodwill during the year		115
Goodwill additions during the year	42,109
Goodwill balance at end of period	$ 75,845	$ 33,736

Composition of certain financ_9

Composition of certain financial statement captions - Schedule of accounts receivable (Details) - USD ($) $ in Thousands	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2022
Composition Of Certain Financial Statement [Abstract]
Billed	$ 62,880	$ 51,458
Unbilled	3,375	989
Total accounts receivable, gross	66,255	52,447
Less: accounts receivable allowances	(1,392)	(1,053)	$ (863)
Total accounts receivable	$ 64,863	$ 51,394

Composition of certain finan_10

Composition of certain financial statement captions - Schedule of allowance for doubtful accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2024	Jan. 31, 2023
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Allowance for doubtful accounts at beginning of period	$ 1,053	$ 863
Bad debt expense	377	587
Increases due to acquisitions	681
Write-offs and adjustments	(719)	(397)
Allowance for doubtful accounts at end of period	$ 1,392	$ 1,053

Composition of certain finan_11

Composition of certain financial statement captions - Schedule of prepaid and other current assets (Details) - USD ($) $ in Thousands	Jan. 31, 2024	Jan. 31, 2023
Composition Of Certain Financial Statement [Abstract]
Prepaid software and business systems	$ 4,922	$ 3,426
Prepaid data center expenses	3,872	2,389
Prepaid insurance	1,257	1,552
Other prepaid expenses and other current assets	4,410	3,342
Total prepaid and other current assets	$ 14,461	$ 10,709

Revenue and contract costs - Na

Revenue and contract costs - Narrative (Details) - USD ($)	12 Months Ended
	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2022
Revenue from External Customer [Line Items]
Settlement period (in days)	2 days
Capitalized contract cost, amortization	$ 1,056,000	$ 1,696,000	$ 2,211,000
Capitalized contract cost, impairment loss	$ 0	0	0
Minimum
Revenue from External Customer [Line Items]
Settlement period (in days)	1 day
Capitalized contract cost, amortization period (in years)	3 years
Maximum
Revenue from External Customer [Line Items]
Settlement period (in days)	2 days
Capitalized contract cost, amortization period (in years)	5 years
Subscription and Related Services
Revenue from External Customer [Line Items]
Lease income	$ 10,307,000	$ 10,197,000	$ 6,489,000

Revenue and contract costs - Ro

Revenue and contract costs - Rollforward of contract assets and contract liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2024	Jan. 31, 2023
Contract With Customer Asset [Roll Forward]
Beginning balance - Contract assets (unbilled accounts receivable)	$ 989	$ 392
Amount transferred to receivables from beginning balance of contract assets	(989)	(392)
Contract asset additions, net of reclassification to receivables	3,375	989
Ending balance - Contract assets (unbilled accounts receivable)	3,375	989
Contract With Customer Liability [Roll Forward]
Beginning balance - Contract liabilities (deferred revenue)	17,813	16,558
Revenue recognized that was included in deferred revenue at the beginning of the period	(17,388)	(16,005)
Deferred revenue added from acquisitions	5,665	0
Other current year activity in deferred revenue	18,120	17,260
Ending balance - Contract liabilities (deferred revenue)	$ 24,210	$ 17,813

Revenue and contract costs - Sc

Revenue and contract costs - Schedule of deferred contract acquisition costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2022
Capitalized Contract Cost [Roll Forward]
Capitalized contract costs at beginning of period	$ 2,810	$ 4,079
Additions to deferred contract acquisition costs	0	427
Amortization of deferred contract acquisition costs	(1,056)	(1,696)	$ (2,211)
Capitalized contract costs at end of period	1,754	2,810	4,079
Deferred contract acquisition costs, current (to be amortized in next 12 months)	768	1,056
Deferred contract acquisition costs, non-current	986	1,754
Total deferred contract acquisition costs	$ 1,754	$ 2,810	$ 4,079

Finance leases and other debt -

Finance leases and other debt - Schedule of outstanding loan balances (Details) - USD ($) $ in Thousands	Jan. 31, 2024	Jan. 31, 2023
Debt Instrument [Line Items]
Finance leases	$ 8,309	$ 7,651
Long-term debt	3,147
Total finance lease liabilities and other debt	11,456	7,897
Less: current portion of finance lease liabilities and other debt	(6,056)	(5,172)
Long-term finance lease liabilities and other debt	5,400	2,725
Financing arrangements
Debt Instrument [Line Items]
Long-term debt	3,124	46
Accrued interest and payments
Debt Instrument [Line Items]
Long-term debt	$ 23	$ 200

Finance leases and other debt_2

Finance leases and other debt - Additional Information (Details) - USD ($)				12 Months Ended
	Dec. 04, 2023	Jun. 08, 2023	Mar. 28, 2022	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2022	Mar. 27, 2022	May 05, 2020	Feb. 28, 2019
Debt Instrument [Line Items]
Long-term debt				$ 3,147,000
Loss on extinguishment of debt				1,118,000	$ 0	$ 0
Term loan
Debt Instrument [Line Items]
Debt instrument, face amount									$ 20,000,000
Financing arrangements
Debt Instrument [Line Items]
Long-term debt				3,124,000	46,000
Installment payment, amount		$ 123,000
Debt instrument, term		36 months
Effective interest rate percentage		10.50%
Revolving Credit Facility | Second SVB Facility
Debt Instrument [Line Items]
Line of credit borrowing capacity								$ 50,000,000
Revolving Credit Facility | Third SVB Facility
Debt Instrument [Line Items]
Line of credit borrowing capacity			$ 100,000				$ 50,000
Stated interest rate (as a percent)			3.25%
Annual commitment fee			$ 250,000
Quarterly fee (as a percent)			0.15%
Revolving Credit Facility | Third SVB Facility | Prime Rate
Debt Instrument [Line Items]
Scheduled reduction in interest rate (as a percent)			0.50%
Line of Credit | Third SVB Facility | Revolving Credit Facility
Debt Instrument [Line Items]
Long-term debt				$ 0	$ 0
Loss on extinguishment of debt	$ 1,118,000
Termination fees	612,000
Write off of unamortized deferred financing costs	$ 506,000
Line of Credit | Senior Secured Asset-based Revolving Credit Facility | Revolving Credit Facility
Debt Instrument [Line Items]
Debt instrument, term	5 years
Line of credit borrowing capacity	$ 50,000,000
Quarterly fee (as a percent)	0.25%
Interest rate (as a percent)				8.30%
Debt issuance costs	$ 778,000
Line of Credit | Senior Secured Asset-based Revolving Credit Facility | Bridge Loan
Debt Instrument [Line Items]
Line of credit borrowing capacity	5,000,000
Line of Credit | Senior Secured Asset-based Revolving Credit Facility | Letter of Credit
Debt Instrument [Line Items]
Line of credit borrowing capacity	$ 5,000,000

Finance leases and other debt_3

Finance leases and other debt - Schedule of Maturities of Finance Leases and Other Debt (Details) - USD ($) $ in Thousands	Jan. 31, 2024	Jan. 31, 2023
Total
2025	$ 6,056
2026	4,167
2027	1,233
Total maturities of finance leases and other debt	11,456
Finance Leases
2025	4,958
2026	2,837
2027	514
Total finance lease liabilities	8,309	$ 7,651
Other Debt
2025	1,098
2026	1,330
2027	719
Total maturities of finance leases and other debt	$ 3,147

Finance leases and other debt_4

Finance leases and other debt - Schedule of interest income (expense), net (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2022
Debt Disclosure [Abstract]
Interest expense	$ (1,854)	$ (1,411)	$ (1,163)
Interest income	4,065	2,475	79
Interest income (expense), net	$ 2,211	$ 1,064	$ (1,084)

Stockholders' Equity (Details)

Stockholders' Equity (Details) - $ / shares				12 Months Ended
	Aug. 11, 2023	Jun. 30, 2023	Apr. 12, 2021	Jan. 31, 2024	Jan. 31, 2022	Jan. 31, 2023	Jul. 22, 2019
Class of Stock [Line Items]
Common stock, authorized (in shares)				500,000,000		500,000,000	500,000,000
Common stock, par value per share (in dollars per share)				$ 0.01		$ 0.01	$ 0.01
Shares withheld for tax withholding obligation				0
Common stock
Class of Stock [Line Items]
Issuance of common stock in follow-on public offering, net (in shares)					5,175,000
MediFind
Class of Stock [Line Items]
Common stock, par value per share (in dollars per share)		$ 0.01
MediFind | Common stock
Class of Stock [Line Items]
Business acquisition, shares (in shares)		150,786
Access
Class of Stock [Line Items]
Common stock, par value per share (in dollars per share)	$ 0.01
Access | Common stock
Class of Stock [Line Items]
Business acquisition, shares (in shares)	1,096,436
Follow-on Offering
Class of Stock [Line Items]
Issuance of common stock in follow-on public offering, net (in shares)			5,175,000
Issue price per share (in dollars per share)			$ 50

Equity-based compensation - Nar

Equity-based compensation - Narrative (Details) $ / shares in Units, $ in Thousands				1 Months Ended	12 Months Ended
	Jan. 02, 2023	Jan. 01, 2021	Dec. 31, 2020	Jun. 30, 2019 shares	Jan. 31, 2024 USD ($) $ / shares shares	Jan. 31, 2023 USD ($) offering_period $ / shares shares	Dec. 31, 2022	Jan. 31, 2022 USD ($) $ / shares shares	Jul. 31, 2023 shares	Jan. 31, 2018 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Minimum shares earned, minimum target percentage					60%
Maximum shares earned, minimum target percentage					90%
Weighted average fair market value of grants (in USD per share) | $ / shares					$ 29.08	$ 26.79		$ 46.60
Intrinsic value | $					$ 6,059	$ 6,970		$ 73,624
Issuance of common stock for employee stock purchase plan | $					$ 3,235	$ 3,472		$ 1,506
Common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase of ESPP settlement (in shares)					141,121	162,154		42,530
Issuance of common stock for employee stock purchase plan | $					$ 1	$ 2
Common Stock Including Additional Paid in Capital
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock for employee stock purchase plan | $					3,235
Additional paid-in capital
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock for employee stock purchase plan | $					3,234	$ 3,470		$ 1,506
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
ESPP, employee common stock purchase discount (as a percent)						15%
Unrecognized compensation costs | $					$ 616
Weighted average term for recognition (in years)					5 months
Employee purchase price of common stock (as a percent)					85%
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting term (in years)			7 years
Unrecognized compensation costs | $					$ 100,100
Weighted average term for recognition (in years)					2 years 7 months 6 days
Bonus settlement in shares (as a percent)					115%
Awards vested during period (in shares)					1,912,432	1,626,679		559,767
RSUs | Employees Other than NEOs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting term (in years)		4 years
Quarterly vesting rate (as a percent)		6.25%
RSUs | NEOs and Other Members of Executive Management
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting term (in years)	4 years						4 years
Quarterly vesting rate (as a percent)	25%						6.25%
RSUs | Share-based Payment Arrangement, Year 1
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting term (in years)			1 year
Percentage of vest option (as a percent)			10%
RSUs | Share-based Payment Arrangement, Year 2
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting term (in years)			2 years
Percentage of vest option (as a percent)			20%
RSUs | Share-based Payment Arrangement, Year 3
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting term (in years)			3 years
Percentage of vest option (as a percent)			30%
RSUs | Share-based Payment Arrangement, Year 4
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting term (in years)			4 years
Percentage of vest option (as a percent)			40%
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost | $					$ 0
Vesting term (in years)					4 years
Expiration period / maximum term (in years)					10 years
PSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting term (in years)					3 years
Percentage of vest option (as a percent)					100%
Unrecognized compensation costs | $					$ 32,077
Weighted average term for recognition (in years)					2 years 4 months 24 days
Weighted average fair market value of grants (in USD per share) | $ / shares					$ 36.42	$ 56.52		$ 48.47
Awards vested during period (in shares)					67,251	0
PSUs | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vest option (as a percent)					0%
PSUs | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vest option (as a percent)					220%	200%		200%
2018 Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for issuance (in shares)										3,048,490
2019 Stock Option And Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserve for future issuance (in shares)				2,139,683
Percentage increase in number of shares reserved (as a percent)				5%
2019 Stock Option And Incentive Plan | ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for grant (in shares)				855,873	4,303,135
Additional shares authorized (in shares)					418,434
ESPP, number of offering periods per year | offering_period						2
ESPP offering period (in months)						6 months
2019 Stock Option And Incentive Plan | Stock options | Share-based Payment Arrangement, Year 1
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting term (in years)					1 year
Percentage of vest option (as a percent)					25%
2019 Stock Option And Incentive Plan | Stock options | Share-based Payment Arrangement, Year 2
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting term (in years)					1 year
Percentage of vest option (as a percent)					25%
2019 Stock Option And Incentive Plan | Stock options | Share-based Payment Arrangement, Year 3
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting term (in years)					1 year
Percentage of vest option (as a percent)					25%
2019 Stock Option And Incentive Plan | Stock options | Share-based Payment Arrangement, Year 4
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting term (in years)					1 year
Percentage of vest option (as a percent)					25%
2023 Inducement Award Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserve for future issuance (in shares)									500,000
2023 Inducement Award Plan | RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for grant (in shares)					475,875
Equity instruments, outstanding, number (in shares)					24,125

Equity-based compensation - Sto

Equity-based compensation - Stock-based compensation (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock based compensation	$ 73,028	$ 60,147	$ 36,723
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock based compensation	53,474	42,214	24,222
Liability awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock based compensation	9,047	7,641	7,055
PSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock based compensation	9,206	7,282	2,389
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock based compensation	45	1,489	2,294
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock based compensation	$ 1,256	$ 1,521	$ 763

Equity-based compensation - S_2

Equity-based compensation - Stock-based compensation in our financial statements (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	$ 73,028	$ 60,147	$ 36,723
Less: stock-based compensation expense capitalized as internal-use software	(1,415)	(1,372)	(489)
Stock-based compensation expense per consolidated statements of operations	71,613	58,775	36,234
Stock-based compensation expense	71,613	58,775	36,144
Cash settled stock based compensation expense			90
Additional paid-in capital
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	63,981	52,506	29,668
Stock-based compensation expense recorded to accrued expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	$ 9,047	$ 7,641	$ 7,055

Equity-based compensation - Per

Equity-based compensation - Performance-based restricted stock units (Details) - shares	12 Months Ended
	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2022
RSUs
Restricted Stock Unit Activity:
Beginning balance (in shares)	3,917,753	3,133,839	2,053,038
Granted (in shares)	2,419,679	2,907,838	1,836,534
Vested (in shares)	(1,912,432)	(1,626,679)	(559,767)
Forfeited and expired (in shares)	(624,790)	(497,245)	(195,966)
Ending balance (in shares)	3,800,210	3,917,753	3,133,839
RSUs | 2023 Inducement Award Plan
Restricted Stock Unit Activity:
Granted (in shares)	24,125
PSUs
Restricted Stock Unit Activity:
Beginning balance (in shares)	648,233	396,216	70,806
Granted (in shares)	576,680	255,572	325,410
Vested (in shares)	(67,251)	0
Forfeited and expired (in shares)	(117,443)	(3,555)
Ending balance (in shares)	1,040,219	648,233	396,216

Equity-based compensation - S_3

Equity-based compensation - Stock option activity (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2022
Number of options
Number of options outstanding at beginning of period (in shares)	1,385,193	1,705,150	3,211,354
Granted (in shares)	0	0	0
Exercised (in shares)	(249,247)	(311,743)	(1,439,186)
Forfeited and expired (in shares)	(12,508)	(8,214)	(67,018)
Number of options outstanding at end of period (in shares)	1,123,438	1,385,193	1,705,150
Exercisable (in shares)	1,123,438
Amount vested at the end of the period (in shares)	24,565
Weighted- average exercise price
Weighted- average exercise price outstanding at beginning of period (in dollars per share)	$ 6.26	$ 6.01	$ 4.67
Granted (in dollars per share)	0	0	0
Exercised (in dollars per share)	3.42	4.92	2.88
Forfeited and expired (in dollars per share)	5.87	4.68	9.02
Weighted- average exercise price outstanding at end of period (in dollars per share)	6.89	$ 6.26	$ 6.01
Exercisable (in dollars per share)	6.89
Amount vested at the end of the period (in dollars per share)	$ 13.41
Weighted-average remaining contractual life of options outstanding and expected to vest (in years)	4 years 6 months 14 days	5 years 21 days	5 years 11 months 8 days
Weighted-average remaining contractual life of options exercisable (in years)	4 years 6 months 14 days
Aggregate intrinsic value outstanding and expected to vest	$ 20,884	$ 43,341	$ 42,938
Aggregate intrinsic value exercisable	$ 20,884

Equity-based compensation - Val

Equity-based compensation - Valuation allowance of performance-based restricted stock units (Details)	12 Months Ended
	Jan. 31, 2024 $ / shares	Jan. 31, 2023 $ / shares	Jan. 31, 2022 $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average fair market value of grants (in USD per share)	$ 29.08	$ 26.79	$ 46.60
PSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Correlation coefficient	0.5238	0.4957	0.3878
Valuation date stock price (in USD per share)	$ 22.94	$ 35.41	$ 36.03
Simulation term (in years)	3 years	3 years	2 years 11 months 26 days
Volatility (as a percent)	64.58%	64.98%	44.32%
Risk-free rate (as a percent)	4.05%	3.84%	1.23%
Dividend yield (as a percent)	0%	0%	0%
Weighted average fair market value of grants (in USD per share)	$ 36.42	$ 56.52	$ 48.47

Equity-based compensation - Wei

Equity-based compensation - Weighted average assumptions (Details) - ESPP	12 Months Ended
	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate (as a percent)	5.30%	3.68%	0.17%
Expected dividends (as a percent)	0%	0%	0%
Expected term (in years)	5 months 26 days	5 months 19 days	5 months 26 days
Volatility (as a percent)	62.40%	74.80%	55.70%

Fair value measurements - Sched

Fair value measurements - Schedule of assets and liabilities measured at fair value (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Jan. 31, 2024	Jan. 31, 2023
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Money market mutual funds	$ 58,942	$ 163,563
Total assets	58,942	163,563
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Money market mutual funds	58,942	163,563
Total assets	58,942	163,563
Significant Other Observable Inputs (Level 2)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Money market mutual funds	0	0
Total assets	0	0
Significant Unobservable Inputs (Level 3)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Money market mutual funds	0	0
Total assets	$ 0	$ 0

Leases - Narrative (Details)

Leases - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2022
Lessee, Lease, Description [Line Items]
Operating lease, weighted average remaining lease term (in years)	1 year 3 months 18 days
Operating lease, weighted average discount rate (as a percent)	5%
Finance lease, weighted average remaining lease term (in years)	1 year 9 months 18 days
Finance lease, weighted average discount rate (as a percent)	6.30%
Computer equipment
Lessee, Lease, Description [Line Items]
Lessee, finance lease, lease not yet commenced, undiscounted payments	$ 7,413
Subscription and Related Services
Lessee, Lease, Description [Line Items]
Lease income	$ 10,307	$ 10,197	$ 6,489
Computer equipment | Minimum
Lessee, Lease, Description [Line Items]
Finance lease, term of contract (in years)	2 years
Computer equipment | Maximum
Lessee, Lease, Description [Line Items]
Finance lease, term of contract (in years)	3 years

Leases - Schedule of operating

Leases - Schedule of operating and finance leases (Details) - USD ($) $ in Thousands	Jan. 31, 2024	Jan. 31, 2023
Leases [Abstract]
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Property and equipment, net of accumulated depreciation and amortization of $76,859 and $59,847 as of January 31, 2024 and 2023, respectively	Property and equipment, net of accumulated depreciation and amortization of $76,859 and $59,847 as of January 31, 2024 and 2023, respectively
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]	Long-Term Debt and Lease Obligation, Current	Long-Term Debt and Lease Obligation, Current
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Long-term finance lease liabilities and other debt	Long-term finance lease liabilities and other debt
Operating leases:
Lease right-of-use assets	$ 266	$ 569
Lease liabilities, current	393	934
Lease liabilities, non-current	134	349
Total operating lease liabilities	527	1,283
Finance leases:
Property and equipment, at cost	35,250	27,813
Accumulated depreciation	(27,399)	(20,657)
Property and equipment, net	7,851	7,156
Lease liabilities, current (included in Current portion of finance lease liabilities and other debt)	4,958	4,926
Lease liabilities, non-current (included in Long-term finance lease liabilities and other debt)	3,351	2,725
Total finance lease liabilities	$ 8,309	$ 7,651

Leases - Schedule of lease expe

Leases - Schedule of lease expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2022
Operating leases:
Operating lease cost	$ 740	$ 1,835	$ 1,096
Variable lease cost	47	62	223
Total operating lease cost	787	1,897	1,319
Finance leases:
Amortization of right-of-use assets	6,742	5,632	4,636
Interest on lease liabilities	580	368	378
Total finance lease cost	$ 7,322	$ 6,000	$ 5,014

Leases - Schedule of maturing l

Leases - Schedule of maturing lease payments (Details) - USD ($) $ in Thousands	Jan. 31, 2024	Jan. 31, 2023
Operating
2025	$ 404
2026	86
2027	42
2028	7
Total future minimum lease payments	539
Less: interest	(12)
Total operating lease liabilities	527	$ 1,283
Finance
2025	5,343
2026	2,986
2027	521
2028	0
Total future minimum lease payments	8,850
Less: interest	(541)
Finance leases	$ 8,309	$ 7,651

Leases - Schedule of supplement

Leases - Schedule of supplemental cash flow information (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash used for operating leases	$ 1,238	$ 1,347	$ 1,206
Operating cash used for finance leases	535	396	377
Financing cash used for finance leases	$ 6,779	$ 5,731	$ 4,267

Commitments and contingencies_2

Commitments and contingencies (Details) $ in Thousands	Jan. 31, 2024 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2025	$ 15,067
2026	9,171
2027	4,520
2028	2,260
Total	$ 31,018

Income taxes - Narratives (Deta

Income taxes - Narratives (Details) - USD ($)	12 Months Ended
	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2022
Operating Loss Carryforwards [Line Items]
Provision for income taxes	$ 1,543,000	$ 483,000	$ 182,000
Effective tax rate (as a percent)	(1.10%)	(0.30%)	(0.20%)
Deferred tax assets, valuation allowance	$ 176,641,000	$ 143,135,000
Increase in valuation allowance	33,506,000
Unrecognized tax benefits	1,240,000	0
Tax examination, penalties and interest accrued	$ 0
Research Tax Credit Carryforward
Operating Loss Carryforwards [Line Items]
Tax credit carryforward, expiration period	20 years
Domestic Tax Authority
Operating Loss Carryforwards [Line Items]
Net operating loss carryforward	$ 598,975,000	$ 493,333,000
Foreign Tax Authority
Operating Loss Carryforwards [Line Items]
Net operating loss carryforward	$ 0

Income taxes - Components of ta

Income taxes - Components of tax (benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2022
Current tax
Federal	$ 0	$ 0	$ 0
State	76	49	39
Foreign	1,239	0	0
Deferred tax
Federal	38	109	0
State	0	0	0
Foreign	190	325	143
Total provision for income taxes	$ 1,543	$ 483	$ 182

Income taxes - Effective tax ra

Income taxes - Effective tax rate reconciliation (Details)	12 Months Ended
	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2022
Income Tax Disclosure [Abstract]
Federal income tax benefit at statutory rate (as a percent)	21%	21%	21%
State and local tax, net of federal benefit (as a percent)	3%	5%	9%
Permanent differences (as a percent)	0%	0%	0%
Equity compensation (as a percent)	0%	0%	6%
Foreign taxes (as a percent)	(1.00%)	0%	0%
Other (as a percent)	0%	0%	0%
Change in valuation allowance (as a percent)	(24.00%)	(26.00%)	(36.00%)
Effective income tax rate (as a percent)	(1.10%)	(0.30%)	(0.20%)

Income taxes - Company's deferr

Income taxes - Company's deferred tax assets and deferred tax liabilities (Details) - USD ($) $ in Thousands	Jan. 31, 2024	Jan. 31, 2023
Deferred tax assets
Net operating loss carryforwards	$ 160,791	$ 131,574
Stock based compensation	9,278	7,765
Accruals, reserves, and other expenses	3,668	2,763
Reserve for bad debts	793	530
Disallowed interest expense	1,041	1,934
Depreciation and amortization	1,829	0
Total deferred tax assets	177,400	144,566
Less: valuation allowance	(176,641)	(143,135)
Net deferred tax (liabilities) assets	759	1,431
Depreciation and amortization	0	(295)
Intangible assets	(569)	(305)
Deferred contract acquisition costs	(460)	(750)
Total deferred tax liabilities	(1,029)	(1,350)
Net deferred tax liabilities	$ (270)
Net deferred tax assets		$ 81

Income taxes - Unrecognized tax

Income taxes - Unrecognized tax benefits (Details) $ in Thousands	12 Months Ended
	Jan. 31, 2024 USD ($)
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance, January 31, 2023	$ 0
Increases for income tax positions related to prior years	844
Increases for income tax positions related to current years	396
Balance, January 31, 2024	$ 1,240

Net loss per share attributab_3

Net loss per share attributable to common stockholders - Schedule of computation (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2022
Numerator:
Net loss	$ (136,885)	$ (176,146)	$ (118,161)
Denominator:
Weighted-average common shares outstanding - basic (in shares)	54,561,449	52,440,067	49,888,436
Weighted-average common shares outstanding - diluted (in shares)	54,561,449	52,440,067	49,888,436
Net loss per share attributable to common stockholders - basic (in dollars per share)	$ (2.51)	$ (3.36)	$ (2.37)
Net loss per share attributable to common stockholders - diluted (in dollars per share)	$ (2.51)	$ (3.36)	$ (2.37)

Net loss per share attributab_4

Net loss per share attributable to common stockholders - Schedule of antidilutive securities (Details) - shares	12 Months Ended
	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	7,365,073	6,820,276	5,708,193
Stock options to purchase common stock, restricted stock units and performance stock awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	7,273,621	6,745,591	5,632,823
Employee stock purchase plan
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	91,452	74,685	75,370

Retirement savings plan (Detail

Retirement savings plan (Details) - USD ($)	12 Months Ended
	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2022
Retirement Benefits [Abstract]
Company contributions	$ 0	$ 0	$ 0

Related party transactions (Det

Related party transactions (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2022
Related Party Transaction [Line Items]
Revenues	$ 356,299	$ 280,910	$ 213,233
Accounts receivable	64,863	51,394
General and administrative	79,926	80,384	$ 68,674
Prepaid expenses and other current assets	14,461	10,709
Related Party
Related Party Transaction [Line Items]
Revenues	1,174	775
Accounts receivable	416	339
General and administrative	$ 118	374
Prepaid expenses and other current assets		$ 51

Acquisitions - Narrative (Detai

Acquisitions - Narrative (Details) $ in Thousands					12 Months Ended
	Oct. 03, 2023 USD ($) installment	Aug. 11, 2023 USD ($) shares	Jun. 30, 2023 USD ($) shares	Dec. 03, 2021 USD ($)	Jan. 31, 2024 USD ($)	Jan. 31, 2023 USD ($)	Jan. 31, 2022 USD ($)
Business Acquisition [Line Items]
Total consideration transferred					$ 60,228
Interest expense					$ 1,854	$ 1,411	$ 1,163
MediFind
Business Acquisition [Line Items]
Percentage of equity acquired (as a percent)			100%
Total consideration transferred			$ 8,871
Weighted average amortization period (in years)			10 years
MediFind | Common stock
Business Acquisition [Line Items]
Business acquisition, shares (in shares) | shares			150,786
Access
Business Acquisition [Line Items]
Percentage of equity acquired (as a percent)		100%
Total consideration transferred		$ 37,411
Weighted average amortization period (in years)		13 years
Access | Common stock
Business Acquisition [Line Items]
Business acquisition, shares (in shares) | shares		1,096,436
ConnectOnCall
Business Acquisition [Line Items]
Percentage of equity acquired (as a percent)	100%
Total consideration transferred	$ 13,946
Number of quarterly installments | installment	7
Appropriate credit-adjusted discount rate (as a percent)					9.30%
Interest accrual per annum (as a percent)					9.30%
Interest expense					$ 294
Consideration transferred to acquire, undiscounted payments					10,937
Weighted average amortization period (in years)	8 years
MediFind, Access, and ConnectOnCall
Business Acquisition [Line Items]
Acquisition related costs incurred					$ 3,106
Insignia
Business Acquisition [Line Items]
Percentage of equity acquired (as a percent)				100%
Total consideration transferred				$ 37,208
Acquisition related costs incurred							$ 720

Acquisitions - Schedule of Medi

Acquisitions - Schedule of MediFind Purchase Price Consideration (Details) - USD ($) $ in Thousands					12 Months Ended
	Oct. 03, 2023	Aug. 11, 2023	Jun. 30, 2023	Dec. 03, 2021	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2022
Business Acquisition [Line Items]
Cash consideration paid to sellers					$ 14,907
Equity consideration paid to sellers					35,321	$ 0	$ 0
Liabilities incurred to sellers					10,000
Total fair value of acquisition consideration					60,228
MediFind
Business Acquisition [Line Items]
Cash consideration paid to sellers			$ 4,195		4,195
Equity consideration paid to sellers			4,676
Liabilities incurred to sellers			0
Total fair value of acquisition consideration			$ 8,871
Access
Business Acquisition [Line Items]
Cash consideration paid to sellers		$ 6,766			6,766
Equity consideration paid to sellers		30,645
Liabilities incurred to sellers		0
Total fair value of acquisition consideration		$ 37,411
ConnectOnCall
Business Acquisition [Line Items]
Cash consideration paid to sellers	$ 3,946				$ 3,946
Equity consideration paid to sellers	0
Liabilities incurred to sellers	10,000
Total fair value of acquisition consideration	$ 13,946
Insignia
Business Acquisition [Line Items]
Cash consideration paid to sellers				$ 37,112
Liabilities incurred to sellers				96
Total fair value of acquisition consideration				$ 37,208

Acquisitions - Schedule of Cons

Acquisitions - Schedule of Consideration Paid (Details) - USD ($) $ in Thousands					12 Months Ended
	Oct. 03, 2023	Aug. 11, 2023	Jun. 30, 2023	Dec. 03, 2021	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2022
Business Acquisition [Line Items]
Cash consideration paid to sellers					$ 14,907
Less: cash acquired					(334)
Cash paid for acquisitions, net of cash acquired per statement of cash flows					14,573	$ 0	$ 34,423
MediFind
Business Acquisition [Line Items]
Cash consideration paid to sellers			$ 4,195		4,195
Less: cash acquired					(231)
Cash paid for acquisitions, net of cash acquired per statement of cash flows					3,964
Access
Business Acquisition [Line Items]
Cash consideration paid to sellers		$ 6,766			6,766
Less: cash acquired					(80)
Cash paid for acquisitions, net of cash acquired per statement of cash flows					6,686
ConnectOnCall
Business Acquisition [Line Items]
Cash consideration paid to sellers	$ 3,946				3,946
Less: cash acquired					(23)
Cash paid for acquisitions, net of cash acquired per statement of cash flows					$ 3,923
Insignia
Business Acquisition [Line Items]
Cash consideration paid to sellers				$ 37,112
Less: cash acquired				(2,689)
Cash paid for acquisitions, net of cash acquired per statement of cash flows				$ 34,423

Acquisitions - Schedule of Fina

Acquisitions - Schedule of Final Allocation of MediFind Purchase Price (Details) - USD ($) $ in Thousands	Jan. 31, 2024	Oct. 03, 2023	Aug. 11, 2023	Jun. 30, 2023	Jan. 31, 2023	Jan. 31, 2022
Business Acquisition [Line Items]
Cash		$ 334
Accounts receivable		2,263
Other current assets		865
Identified intangible assets acquired		22,600
Goodwill	$ 75,845	42,109			$ 33,736	$ 33,621
Total assets acquired		68,171
Accounts payable		(406)
Accrued liabilities		(1,749)
Deferred revenue		(5,665)
Deferred income tax liabilities		(123)
Total purchase price		60,228
MediFind
Business Acquisition [Line Items]
Cash				$ 231
Accounts receivable				149
Other current assets				722
Identified intangible assets acquired				2,300
Goodwill				6,821
Total assets acquired				10,223
Accounts payable				(121)
Accrued liabilities				(816)
Deferred revenue				(292)
Deferred income tax liabilities				(123)
Total purchase price				$ 8,871
Access
Business Acquisition [Line Items]
Cash			$ 80
Accounts receivable			1,870
Other current assets			110
Identified intangible assets acquired			18,300
Goodwill			23,426
Total assets acquired			43,786
Accounts payable			(196)
Accrued liabilities			(884)
Deferred revenue			(5,295)
Deferred income tax liabilities			0
Total purchase price			$ 37,411
ConnectOnCall
Business Acquisition [Line Items]
Cash		23
Accounts receivable		244
Other current assets		33
Identified intangible assets acquired		2,000
Goodwill		11,862
Total assets acquired		14,162
Accounts payable		(89)
Accrued liabilities		(49)
Deferred revenue		(78)
Deferred income tax liabilities		0
Total purchase price		$ 13,946

Acquisitions - Schedule of Inta

Acquisitions - Schedule of Intangible Asset Acquired Related to MediFind Acquisition (Details) - USD ($) $ in Thousands	Jan. 31, 2024	Oct. 03, 2023	Aug. 11, 2023	Jun. 30, 2023
Trademark
Acquired Finite-Lived Intangible Assets [Line Items]
Estimated useful life (in years)	15 years
MediFind
Acquired Finite-Lived Intangible Assets [Line Items]
Fair Value				$ 2,300
MediFind | Technology
Acquired Finite-Lived Intangible Assets [Line Items]
Estimated useful life (in years)				7 years
Fair Value				$ 1,200
MediFind | Trademark
Acquired Finite-Lived Intangible Assets [Line Items]
Estimated useful life (in years)				15 years
Fair Value				$ 700
MediFind | Customer relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Estimated useful life (in years)				10 years
Fair Value				$ 400
Access
Acquired Finite-Lived Intangible Assets [Line Items]
Fair Value			$ 18,300
Access | Technology
Acquired Finite-Lived Intangible Assets [Line Items]
Estimated useful life (in years)			7 years
Fair Value			$ 5,200
Access | Trademark
Acquired Finite-Lived Intangible Assets [Line Items]
Estimated useful life (in years)			15 years
Fair Value			$ 2,400
Access | Customer relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Estimated useful life (in years)			15 years
Fair Value			$ 10,700
ConnectOnCall
Acquired Finite-Lived Intangible Assets [Line Items]
Fair Value		$ 2,000
ConnectOnCall | Technology
Acquired Finite-Lived Intangible Assets [Line Items]
Estimated useful life (in years)		5 years
Fair Value		$ 1,500
ConnectOnCall | Customer relationships
Acquired Finite-Lived Intangible Assets [Line Items]
Estimated useful life (in years)		15 years
Fair Value		$ 500